Document:

Exhibit

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Exhibit 10.43
CONTRACT MANUFACTURING AGREEMENT
This Contract Manufacturing Agreement is made by and between (1) Fresenius Kabi Austria GmbH, having its registered office at Hafnerstrasse 36, A-8055 Graz, Austria (“FRESENIUS”) and (2) AMAG Pharmaceuticals, Inc., a Delaware corporation having an office at 1100 Winter Street, Waltham, MA 02451, U.S.A. (“COMPANY”), effective as of September 1, 2018 (the “Effective Date”).
Recitals
		
	(A)
	WHEREAS, COMPANY holds or is seeking the marketing authorisation of the Product (as defined herein).

		
	(B)
	WHEREAS, COMPANY desires to engage FRESENIUS for the manufacture and supply of the Product which is intended for commercial use.

		
	(C)
	WHEREAS, FRESENIUS desires to manufacture such Product and supply it to COMPANY.

		
	(D)
	WHEREAS, the Parties have agreed to enter into this Agreement to set forth the terms and conditions on which the manufacture and supply of any particular Product under a Product Schedule (as defined herein) will be carried out.

NOW, THEREFORE, the Parties hereto agree as follows:
		
	1.
	Definitions

		
	1.1
	“Affiliate” shall mean any company, corporation, partnership, joint venture and/or firm which, directly or indirectly, controls or is controlled by or is under common control with a Party. As used in the definition of “Affiliate”, “control” means (a) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction), and (b) in the case of non-corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the non-corporate entity or the power to elect more than fifty percent (50%) of the members of the governing body of such non-corporate entity.

		
	1.2
	“Agreement” means this Contract Manufacturing Agreement, together with all Appendices attached hereto, as amended from time to time by the Parties in accordance with Section 26.1, and all fully signed Product Schedules.

		
	1.3
	[***].

		
	1.4
	"Applicable Laws" means the applicable laws, statutes, rules, codes, regulations, orders, judgments and/or ordinances of any Authority related to granting approvals for, or the performance of Services under this Agreement, and/or registration, approval, and/or use of Product in Austria, the European Union, and the United States, as may be in effect from time to time or as any of the same may be amended from time to time, including GMP. 

1

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	1.5
	“Authority” means any government regulatory authority responsible for granting approvals for the performance of Services under this Agreement or for issuing regulations pertaining to the Manufacture and/or use of Product in the intended country of use, including the FDA.

		
	1.6
	“Average Yield” has the meaning set forth in Part C.7 of the applicable Product Schedule. 

		
	1.7
	"Background Intellectual Property" means any and all Intellectual Property of a Party, which, as demonstrated by admissible evidence, (i) already existed as of the Effective Date of this Agreement or (ii) was developed or obtained by or on behalf of such Party independent of this Agreement, and without reliance upon the Confidential Information of the other Party. 

		
	1.8
	“Batch” means a specific quantity of Product that is produced during one instance of Manufacture in accordance with the instructions in the applicable MBR, and which Batch of Product is intended to satisfy Specifications.

		
	1.9
	“Batch Documentation” has the meaning set forth in Section 16.2. 

		
	1.10
	“Business Day” means a day other than Saturday or Sunday or a day that is not a public holiday in the jurisdiction in which COMPANY and/or FRESENIUS are located or a day that is not in the shutdown times at FRESENIUS which COMPANY has been notified of at least [***] in advance of such shutdown.

		
	1.11
	“Certificate of Analysis” means a document signed by an authorized representative of FRESENIUS, describing Specifications for the Product, and the results of testing of the Batch. 

		
	1.12
	“Certificate of Conformity” means a document signed by an authorized representative of FRESENIUS, certifying that a particular Batch was Manufactured in accordance with GMP, this Agreement, and all other requirements of the applicable Quality Agreement.

		
	1.13
	“Change Of Control” means any transaction or series of related transactions involving: (i) the sale, lease, or transfer of all or substantially all of the assets of the COMPANY to any third party; (ii) any merger or consolidation of the COMPANY into or with another person or entity that is a third party (other than a merger or consolidation effected exclusively to change the COMPANY’s domicile or solely for internal restructuring purposes), or any other corporate reorganization, in each case following which the COMPANY is not the surviving or successor entity and the stockholders of the COMPANY in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the surviving or successor entity’s outstanding voting power; or (iii) any sale or other transfer by the stockholders of the COMPANY of shares representing at least a majority of the COMPANY’s then-total outstanding combined voting power. As used in this definition of “Change Of Control”, “third party” means an entity other than an Affiliate of COMPANY.

		
	1.14
	“Change Order” has the meaning in Section 8. 

		
	1.15
	“Confidential Information” means any and all non-public information (a) furnished or disclosed by or on behalf of one Party (“Disclosing Party”) to the other Party (“Receiving Party”) or (b) developed by a Party via the use of Confidential Information under this Agreement or generated in the performance of this Agreement, in either case whether marked “confidential” or not, whether in oral, visual, electronic, written or any other form 

2

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

including, but not limited to, financial data, trade secrets, know-how, forecasts, marketing plans, strategies, inventions, ideas, formulas, processes, test data, procedures, formulations and specifications, and all of those portions of notes, compilations, summaries, memoranda or other documents prepared by the Receiving Party which contain, reflect or are otherwise derived from the before mentioned information as well as any copies thereof and of the before mentioned information.
		
	1.16
	“Effective Date” has the meaning set forth above. 

		
	1.17
	“Facility” means the facility(ies) of FRESENIUS identified in the applicable Product Schedule and any additional facilities to be used for Manufacture of Product as identified in the applicable Quality Agreement. 

		
	1.18
	"FDA" means the United States Food and Drug Administration and any successor agency thereto.

		
	1.19
	[***]. 

		
	1.20
	“Fixed Price Term” means the term for which the Price specified in the relevant Product Schedule will remain fixed, as specified in Part C.3 of the relevant Product Schedule.

		
	1.21
	“Force Majeure” has the meaning in Section 25. 

		
	1.22
	“Forecast” has the meaning set forth in Section 5.1.

		
	1.23
	"GMP" means current good manufacturing practices, rules, regulations and guidelines specified in applicable European Union and Pharmaceutical Inspection Convention and Co-Operating Scheme (PIC/S) directives (and the corresponding national laws and regulations), in the United States Code of Federal Regulations, and in any other applicable laws, rules and regulations and guidelines.

		
	1.24
	"Intellectual Property" means all know-how, copyrights, trademarks, patents, trade secrets, designs, information, documentation, drawings, methods, techniques, data, regulatory submissions, specifications, and other intellectual property of any kind (whether or not protected under patent, trademark, copyright or similar jaws).

		
	1.25
	“Invoice Currency” means the currency in which each Product will be invoiced and paid, as specified in Part C.2 of the relevant Product Schedule.

		
	1.26
	“Loss(es)” shall mean any and all liabilities, costs, damages and expenses, including [***]. 

		
	1.27
	“Manufacturing Activities”, “Manufacture”, “Manufactured”, or “Manufacturing” means any steps, processes and activities necessary for production by FRESENIUS of Product including the manufacturing, processing, packaging, labelling, quality control testing, stability testing, release, storage or supply of Product as required by the applicable Product Schedule, this Agreement, the MBR, and the applicable Quality Agreement. 

		
	1.28
	“Manufacturing Process” means any and all procedures and activities (or any step in any procedure or activity) (a) planned to be used by FRESENIUS to Manufacture Product, as 

3

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

evidenced in the MBR or (b) actually used by FRESENIUS, as evidenced in the Batch Documentation the particular Batch.
		
	1.29
	“MBR” means the version-controlled complete detailed instructions agreed to in writing by the Parties for the Manufacturing Process to be used to Manufacture a Batch of the applicable Product, which may be modified or changed only in accordance with the applicable Quality Agreement. 

		
	1.30
	“Minimum Order Quantities” means the minimum quantity of primary packaging materials that a Designated Supplier (as defined in Section 14.1) will sell per order. 

		
	1.31
	“Parties” means FRESENIUS and COMPANY. “Party” shall mean either FRESENIUS or COMPANY as the context indicates.

		
	1.32
	“Price” means, with respect to the Product, the amount payable for such Product as specified in Part C.1 of the relevant Product Schedule, subject to adjustment as set forth in such Product Schedule.

		
	1.33
	“Product(s)” means, with respect to a Product Schedule, the final form of the product including if applicable Supplied Materials, to be supplied pursuant to and as detailed in Part A of such Product Schedule.

		
	1.34
	“Product Schedule” means a schedule for supply of Product that is executed and delivered by the Parties in accordance with Section 4.

		
	1.35
	“Product Schedule Effective Date” means, with respect to each Product Schedule, the date on which such Product Schedule becomes effective, as set forth in such Product Schedule.

		
	1.36
	“Purchase Order” means a binding order issued by COMPANY pursuant to this Agreement substantially in the form identified in Exhibit 2 for such quantities of a Product as COMPANY desires to purchase from FRESENIUS in accordance with the terms of this Agreement stating, amongst others, purchase order number, COMPANY product code, COMPANY product name, quantities, Prices, desired delivery date and address.

		
	1.37
	“Quality Agreement” means a quality agreement(s) entered into by the Parties, as it may be amended from time to time by the Parties in accordance with its terms, containing quality assurance responsibilities for Product.

		
	1.38
	“Records” have the meaning set forth in Section 9.1. 

		
	1.39
	“Services” means the services to be performed by FRESENIUS under this Agreement. 

		
	1.40
	“Specification(s)” means (a) with respect to each Product Schedule, the specifications for such Product, as specified in Part A of such Product Schedule and/or the applicable Quality Agreement as the same may be updated from time to time in accordance with this Agreement and the respective Quality Agreement.

		
	1.41
	“Supplied Materials” has the meaning set forth in Section 15.1.

4

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	1.42
	“Territory” means all countries or regions in which a commercial sale of the applicable Product is intended to take place as listed in Part A.3 of the relevant Product Schedule.

		
	2.
	General. 

		
	2.1
	Performance of Services. FRESENIUS will perform Services in accordance with this Agreement, the applicable Quality Agreement, the applicable Product Schedule and all Applicable Laws, including GMP. FRESENIUS will perform all Services at the Facility, provide all staff and equipment necessary to perform the Services in accordance with this Agreement, and hold at such Facility all equipment, Supplied Materials and other items used in the Services. FRESENIUS will supply, in accordance with the relevant approved raw material specifications as identified in the applicable Quality Agreement, all materials to be used by FRESENIUS in the performance of Services other than the Supplied Materials. 

		
	2.2
	Facility Requirements. FRESENIUS will not change the location of such Facility or use any additional facility for the performance of Services under this Agreement without prior written notice to, and prior written consent from, COMPANY. FRESENIUS will maintain, at its own expense, the Facility and all equipment required for the Manufacture of Product in a state of repair and operating efficiency consistent with the requirements of GMP and all Applicable Laws, and FRESENIUS Standard Operating Procedures (“SOPs”). FRESENIUS will notify COMPANY of any proposed changes to the Facility, its utilities, layout or other matters that may impact the Product in accordance with the requirements of the applicable Quality Agreement. 

		
	2.3
	Validation. FRESENIUS will be responsible for performing all validation of the Facility, equipment and cleaning and maintenance processes employed in the Manufacturing Process as set forth in the Quality Agreement and if not identified therein in accordance with GMP,  FRESENIUS’ SOPs, and Applicable Laws.

		
	2.4
	Changes to Laws. If there are any material changes in GMP or Applicable Laws enacted after the execution of a Product Schedule that impact the Manufacture of such Product, and such changes are specific to the Product and not of general requirement for contract manufacturing services and [***], then FRESENIUS will promptly provide written notice to COMPANY documenting such change and [***], and the Parties shall in good faith discuss and negotiate ways to continue the Manufacture of Product overcoming [***] and the possibility of a Change Order. In the event the Parties are unable to reach a mutually agreeable arrangement within [***], FRESENIUS may terminate this Agreement by providing COMPANY with written notice of its intent to terminate, with a notice period of [***], beginning with the date such notice is delivered to COMPANY.

		
	2.5
	Subcontracting. FRESENIUS may not subcontract with any third party or any Affiliate of FRESENIUS, to perform any of its obligations under this Agreement without the prior written consent of COMPANY. Such consent shall be deemed given for such third party performing certain Services if such subcontractor is specified in the applicable Quality Agreement as providing such Services. FRESENIUS will be solely responsible for the performance of any permitted subcontractor, and liability arising out of such performance as if such performance had been provided by FRESENIUS itself under this Agreement. FRESENIUS will cause any such permitted subcontractor to be bound by, and to comply with, the terms of this 

5

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Agreement, as applicable, including all confidentiality, quality assurance, regulatory and other obligations and requirements of, FRESENIUS set forth in this Agreement.
		
	2.6
	Duty to Notify. FRESENIUS will promptly notify COMPANY if, at any time during the term of this Agreement, FRESENIUS has reason to believe that it will be unable to perform or complete the Services in a timely manner. Compliance by FRESENIUS with this Section will not relieve FRESENIUS of any other obligation or liability under this Agreement.

		
	2.7
	Ownership of Materials. COMPANY will at all times retain title to and ownership of the Supplied Materials, Product, any intermediates and components of Supplied Materials or Product, and any work in process at each and every stage of the Manufacturing Process, with the exception of packaging material and other materials which are procured by FRESENIUS. Title to and ownership of the FRESENIUS procured materials will be transferred to COMPANY upon delivery of Product to COMPANY. FRESENIUS will provide within the Facility an area or areas where such materials and any work in process are segregated and stored in accordance with the Specifications and GMP, and in such a way as to be able at all times to clearly distinguish such materials from products and materials belonging to FRESENIUS, or held by it for any other party’s account. FRESENIUS will ensure that Supplied Materials, Product, any intermediates and components of any Supplied Materials or Product, and any work in process are free and clear of any liens or encumbrances. FRESENIUS will protect such materials from loss, damage and theft at all stages of the Manufacturing Process, and immediately notifies COMPANY if at any time it believes any such materials have been damaged, lost or stolen.

		
	3.
	Engagement of FRESENIUS.

		
	3.1
	Manufacture of Product. FRESENIUS will Manufacture and sell Product to COMPANY in accordance with the terms of this Agreement and upon terms consistent with any confirmed Purchase Order pursuant to Section 6.2. 

		
	4.
	Product Schedules.

		
	4.1
	The Parties shall enter into a Product Schedule (substantially in the form of Exhibit 1) for each Product that is or may be the subject of a marketing authorization of an Authority that is to be manufactured and supplied subject to the terms and conditions of this Agreement. 

		
	4.2
	Any number of Product Schedules may be executed pursuant to this Agreement. Each Product Schedule will govern the supply of the Product set forth therein.

		
	4.3
	Each Product Schedule will operate for the term specified in that Product Schedule unless earlier terminated in accordance with Section 23 of this Agreement.

		
	5.
	Forecasting; Minimum purchase quantity; Delivery.

		
	5.1
	For every Product Schedule, [***] when such Product Schedule remains in effect, COMPANY shall submit to FRESENIUS a rolling forecast covering each product code set forth in such Product Schedule for COMPANY’s good faith estimate of the quantity of the relevant Product it expects to order from FRESENIUS pursuant to such Product Schedule for the time period of the following [***], broken down on a [***] basis, (each such estimate, a “Forecast”). The first [***] of each Forecast shall be binding to COMPANY (the “Binding 

6

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Forecast”). The Binding Forecasts can only be changed with FRESENIUS written consent. The following [***] after the Binding Forecast period shall be semi-binding on COMPANY, meaning COMPANY may order [***] of the forecasted quantity of Product in such portion of the Forecast (the “Semi-Binding Forecast”) without  FRESENIUS’ prior written consent. The subsequent [***] of each Forecast are estimations and shall be used by FRESENIUS for planning purposes only. 
		
	5.2
	In addition, COMPANY shall submit to FRESENIUS [***] for every Product Schedule in effect a non-binding to [***] Forecast for planning purposes only.

		
	5.3
	Primary packaging materials (as described in the applicable Quality Agreement) used to manufacture the Products can be purchased by FRESENIUS based on [***] rolling forecast figures pursuant to Section 5.1. [***] shall bear all costs of such materials if they expire, including reasonable scrapping costs of the materials if primary packaging materials in stock expire during the term of this Agreement due to [***]. For the avoidance of doubt, any Minimum Order Quantities shall be specified in the applicable Product Schedule. FRESENIUS is responsible for maintaining a sufficient inventory of materials in order to meet its obligations under this Agreement, including the Forecasts, and such materials will be used in a first-expiry, first out (FEFO) basis. 

		
	5.4
	Concerning Product under the Semi-Binding Forecast and Binding Forecasts: if the quantity of Product ordered by COMPANY pursuant to Purchase Orders submitted to FRESENIUS is (a) less than the quantity forecasted in the Binding Forecast for such period, or (b) less than [***] of the quantity forecasted in the Semi-Binding Forecast for such period, then COMPANY shall pay FRESENIUS the compensation specified in Part C.6 of the relevant Product Schedule for such shortfall. For avoidance of doubt, if (x) as set forth in Section 5.1, FRESENIUS provides its written consent to a change in the Binding Forecast, or (y) FRESENIUS is unable to supply the quantity of Product under any Purchase Order that is consistent with the Binding Forecast, FRESENIUS shall not be entitled to such compensation, unless agreed to by COMPANY in a signed writing. 

		
	5.5
	Subject to Section 2.6, based on the analysis of Forecasts it receives from COMPANY, FRESENIUS undertakes to inform COMPANY within [***] of receipt of the Forecast of any significant unavailability of capacity it might face in fulfilling COMPANY’s needs.

		
	5.6
	COMPANY guarantees to purchase and pay a minimum purchase quantity of Product as stated in the relevant Product Schedule under Part B.5. If COMPANY does not purchase the minimum purchase quantity, FRESENIUS is entitled to compensation as defined in Part B.5 to the relevant Product Schedule.

		
	5.7
	The delivery terms for Product are specified in Part B.1 of the relevant Product Schedule.

		
	5.8
	The packaging and labelling requirements are specified in Part B.3 of the relevant Product Schedule.

		
	5.9
	Notwithstanding any terms and conditions in a Product Schedule or this Agreement that obligate COMPANY to purchase a minimum quantity of Product, and pay compensation to FRESENIUS for a failure to purchase such quantities, such purchase obligations and compensation that would otherwise be due from COMPANY will be reduced [***] for Product 

7

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

quantities affected by the events set forth in Sections 5.9(a)-(e) below, if COMPANY cannot fulfil its minimum purchase quantity obligations [***] due to:
		
	(a)
	[***]; 

		
	(b)
	[***];

		
	(c)
	[***]; 

		
	(d)
	[***];

		
	(e)
	[***]. 

		
	6.
	Orders.

		
	6.1
	COMPANY shall submit to FRESENIUS Purchase Orders for its planned requirements of Product under each Product Schedule not less than [***] prior to the required delivery date of the Product. Each Purchase Order shall detail COMPANY’s purchase order number, FRESENIUS’ product codes, and FRESENIUS product names for the Product, as specified in the applicable Product Schedule, as well as the delivery date and required quantities per delivery date. Each Purchase Order shall also include the shipping and invoice address of COMPANY. 

		
	6.2
	All Purchase Orders shall be in writing and be transmitted by facsimile or by email. Each Purchase Order submitted to FRESENIUS by COMPANY that conforms to the requirements of this Agreement, the applicable Product Schedule, and the applicable Forecast shall be confirmed [***] in writing by FRESENIUS at the latest [***] after receipt of each such Purchase Order; provided, that, (i) Purchase Orders are for Product within the Binding Forecast and (ii) FRESENIUS [***] shall act in good faith and use [***] to accept and fulfil any other Purchase Order that is consistent with the Forecast except if FRESENIUS has notified COMPANY of (a) its inability to supply the quantity of Product under Purchase Orders consistent with the Binding Forecast in accordance with Section 5.5 or 25, or (b) an uncured material breach by COMPANY. Each Purchase Order issued by COMPANY pursuant to this Agreement will be subject to the terms of this Agreement and will be incorporated herein and form part of this Agreement. 

		
	6.3
	Confirmed Purchase Orders can only be changed by a mutual written agreement of both Parties. Unless otherwise agreed by the Parties, each Purchase Order shall specify one delivery date for all Batches ordered thereunder. Notwithstanding the foregoing, delivered quantities of Product [***] consistent with the Average Yield set forth in Part C.7 of the applicable Product Schedule. In this event, [***] only the quantities of Product delivered by FRESENIUS to COMPANY are payable by COMPANY.  

		
	6.4
	Product ordered pursuant to confirmed Purchase Orders will be delivered [***] unless otherwise mutually agreed by the Parties in writing, Product shall be delivered at the latest within [***] of the delivery date specified by COMPANY in any Purchase Order that is consistent with the Forecast and Section 6.1.

8

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	7.
	Quality.

		
	7.1
	The Product shall satisfy the Specifications. The Parties shall comply with the provisions and requirements of the relevant Quality Agreement.

		
	7.2
	Each Party shall maintain governmental permits, licenses and approvals enabling such Party to perform its obligations under this Agreement.

		
	7.3
	FRESENIUS shall maintain, at its own expense, governmental permits and licenses for the Facility enabling it to perform its obligations under this Agreement. At COMPANY’s request, FRESENIUS will provide COMPANY with copies of all such permits and licenses, COMPANY will have the right to use any and all information contained in such governmental permits and licenses, in connection with regulatory approval of Product.

		
	7.4
	Further quality relevant issues and the allocation of the responsibilities are listed in the applicable Quality Agreement. The Parties shall comply with the provisions of the applicable Quality Agreement. If there are any direct conflicts between the terms of the applicable Quality Agreement and this Agreement, the provisions in this Agreement shall govern, except that if there is a conflict between this Agreement and the applicable Quality Agreement related to quality matters, the Quality Agreement will prevail.

		
	8
	Unless and until otherwise agreed by the Parties by entering into a new or additional Quality Agreement or otherwise amending the Quality Agreement, the Quality Agreement for Product that is supplied under a Product Schedule will apply to all Products delivered by FRESENIUS to COMPANY under all Product Schedules. If changes to the Specifications or the Quality Agreement are necessary and such changes would materially increase or reduce the costs for FRESENIUS, as documented and reasonably demonstrated to COMPANY, the Parties shall negotiate in good faith a Change Order to modify the Price of the effected Product as well as the fees payable. Changes, Manufacturing Process and Specifications. 

		
	8.1
	Changes. If a required modification to this Agreement, or a Product Schedule, or the Quality Agreement is identified by a Party including as a result of a change in GMP as described in Section 2.4, the identifying Party will notify the other Party in writing as soon as reasonably possible, and FRESENIUS will provide COMPANY with a change order (“Change Order”) containing a description of the required modifications and their effect on the scope, fees, costs and timelines of this Agreement, or Product Schedule or Quality Agreement, as applicable, and will use reasonable efforts to do so within [***] of receiving or providing such notice, as the case may be. No Change Order will be effective unless and until it has been signed by authorized representatives of both Parties. 

		
	8.2
	Process/Specifications Changes. No change or modification to the Manufacturing Process or Specifications for any Product will be made by FRESENIUS unless approved in advance in writing signed by COMPANY and made in accordance with the change control provisions of the applicable Quality Agreement.

		
	9.
	Record and Sample Retention.

		
	9.1
	Records. FRESENIUS will keep complete and accurate records of Batch Documentation of Product and/or other documents related to the Manufacturing Process of Product as 

9

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

required by Applicable Laws, the applicable Quality Agreement, and this Agreement (collectively, the “Records”). All Records will be the property of COMPANY and, except as required by Applicable Laws or to meet its obligations under this Agreement, will not be transferred, delivered or otherwise provided to any party other than COMPANY, without the prior written approval of COMPANY. FRESENIUS will retain Records in accordance with the FRESENIUS SOPs for records retention, the Quality Agreement, and Applicable Laws. COMPANY may require FRESENIUS to provide such Records after the retention period ends. In such case, COMPANY shall inform FRESENIUS in writing at least [***] prior to end of the respective retention period. FRESENIUS shall make the Records available to COMPANY for inspection or copying upon COMPANY’s reasonable request or during audits by COMPANY.  For the avoidance of doubt, nothing in this Section 9.1 is intended to alter or affect the parties’ respective rights pursuant to Section 20.2(b) below.
		
	9.2
	Samples. 

		
	(a)
	Retained Samples. FRESENIUS will take and retain, for such period and in such quantities as required by GMP and the applicable Quality Agreement, samples of Product Manufactured under this Agreement (“Retained Samples”). 

		
	(b)
	Other Samples. From time to time, COMPANY may request from FRESENIUS, and FRESENIUS shall provide to COMPANY or its designee, samples of Product (other than any Retained Samples that FRESENIUS is required to retain pursuant to GMP) in accordance with the applicable Quality Agreement, Section 16.4, or as otherwise reasonably required by COMPANY. Upon COMPANY’s written request, FRESENIUS will provide such samples to COMPANY or its designee in accordance with the applicable Quality Agreement, or if such samples are for a purpose other than as contemplated under the applicable Quality Agreement (such samples, “Other Samples”), FRESENIUS shall provide such Other Samples to COMPANY or its designee in accordance with COMPANY’s reasonable written instructions according to Prices per unit defined in the relevant Product Schedule plus additional out of pocket costs. 

		
	10.
	Regulatory Matters.

		
	10.1
	Regulatory Inspections. 

		
	(a)
	FRESENIUS will inform COMPANY of any unannounced Regulatory Authority inspections that involve the Products within [***]. FRESENIUS will inform COMPANY of any scheduled Authority inspections that involve the Products within [***] of the notification to FRESENIUS of such an inspection. FRESENIUS will permit a representative from COMPANY to be present at the Facility for a pre-approval inspection or any subsequent inspection that directly involves Product. COMPANY personnel will participate in the inspection related to COMPANY’s Products if it so chooses or at the request of the regulatory agency.

		
	(b)
	FRESENIUS will inform COMPANY within [***] of any Authority critical or major findings (i.e. Form 483's, warning letters or such other similar correspondence) that have an impact on the manufacture of the Product. Copies of Authority audit findings and 

10

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

responses will be provided to COMPANY; proprietary information may be redacted unless such information directly relates to COMPANY’s products.
		
	(c)
	COMPANY will maintain reports of any inspection carried out by regulatory authorities at COMPANY’s facilities that are directly related to the Product with details of any major, minor, or adverse comments. For inspections that are specifically related to the manufacture of Product(s) at the Facility, COMPANY will notify FRESENIUS within [***] of the initiation of such inspection and provide updates at regular intervals during such inspection. COMPANY shall make any response to Authorities with respect to such inspections if needed within [***]. Copies of the regulatory agency findings and the site responses specifically relating to the manufacture of Product at the Facility are to be sent to FRESENIUS, redacted if applicable, or confirm absence of observations and/or responses.

		
	10.2
	Inspections/Audits by COMPANY. FRESENIUS will permit COMPANY and/or its representatives to perform audits to inspect the Facility including the Records and the holding facilities for Supplied Materials in an interval, duration, and notice period as defined in the applicable Quality Agreement to ensure compliance with the terms of this Agreement, and (b) for cause with the notice period defined in the applicable Quality Agreement, in each case [***], and as may be further defined in the applicable Quality Agreement. For all other audits by COMPANY or its representatives, such additional audit must be agreed to by the Parties including, [***].

		
	10.3
	Waste Disposal. The generation, collection, storage, handling, transportation, movement and release of hazardous materials and waste generated in connection with the Services will be the responsibility of FRESENIUS at  FRESENIUS’ sole cost and expense except for reasonable costs associated with such activities for hazardous materials that expire (a) due to changes in the [***] rolling Forecast provided by COMPANY provided such changes or hazardous material expiration are unrelated to FRESENIUS acts or omissions, or (b) due to COMPANY’s omissions. Without limiting other applicable requirements, FRESENIUS will prepare, execute and maintain, as the generator of waste, all licenses, registrations, approvals, authorizations, notices, shipping documents and waste manifests required under Applicable Laws.

		
	10.4
	Safety Procedures. FRESENIUS will be solely responsible for implementing and maintaining health and safety procedures for the performance of Services and for the handling of any materials or hazardous waste used in or generated by the Services. FRESENIUS, in consultation with COMPANY, will develop safety and handling procedures for Product; provided, however, that COMPANY will have no responsibility for FRESENIUS’ health and safety program. 

		
	11.
	Price.

		
	11.1
	The Price of each Product is [***]. The Price is payable in the applicable Invoice Currency. Price for Product is indicated in the respective Product Schedule. [***]. 

		
	11.2
	The Price for Product and the period for which it will be valid, and the conditions under which such Price will be reviewed, except as set forth below, are laid out in the relevant Product Schedule. [***].

11

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	11.3
	[***]. 

		
	11.4
	[***]:

		
	a)
	[***].

		
	b)
	[***].

		
	c)
	[***].

		
	d)
	[***].

	
		
	Index
	Internet link

	[***]

	[***]

		
	11.5
	If COMPANY requests specific quality and regulatory activities [***] not defined in the applicable Quality Agreement or that are specifically identified in the applicable Product Schedule as excluded from the Price for such Product, such activities, and the fees associated with such additional activities must be expressly authorized to be performed by COMPANY in writing. [***].

		
	12.
	Invoicing and Payment.

		
	12.1
	All amounts due under this Agreement will be invoiced by FRESENIUS in accordance with this Agreement and the applicable Product Schedule. FRESENIUS shall issue an invoice to COMPANY for the applicable Price for all Products delivered to COMPANY hereunder pursuant to a Product Schedule [***]. Each duly issued invoice shall contain a reference to the Purchase Order number of COMPANY and shall state FRESENIUS’ registered VAT number. 

		
	12.2
	COMPANY shall pay all invoices in full within [***] from the date of receipt of the relevant invoice to the payee set forth in the applicable Product Schedule, unless such invoice is the subject of a good faith dispute in which case COMPANY will promptly advise FRESENIUS of the dispute and the Parties will cooperate with each other to timely resolve such dispute. 

		
	13.
	Shipping and Delivery. 

Delivery terms of Product are defined in the respective Product Schedule. FRESENIUS will not make Product available to COMPANY’s carrier until FRESENIUS has received written instructions from COMPANY to do so. FRESENIUS will ensure that each Batch will be delivered to COMPANY or COMPANY’s designee in accordance with the instructions for shipping and packaging specified by COMPANY in the applicable Product Schedule or otherwise agreed in writing. 

12

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	14.
	Designated Suppliers.

		
	14.1
	The Parties may agree that FRESENIUS will only order certain or all raw material or packaging, which are needed to manufacture the Product, from certain suppliers pre-approved in writing by COMPANY (“Designated Suppliers”). If the Parties agree on Designated Suppliers, these Designated Suppliers will be listed in the relevant Annex of the applicable Quality Agreement. For the avoidance of doubt, the term “Designated Suppliers” does not include suppliers of Supplied Materials (as defined in Section 15.1 below). 

		
	14.2
	COMPANY is responsible for auditing and qualification of Designated Suppliers if expressly agreed to in writing by COMPANY. If a Designated Supplier does not deliver in the quality or time demanded by FRESENIUS or if its deliveries suffer shortfalls, damages or defects, COMPANY and FRESENIUS will negotiate further actions and shall [***] to overcome and resolve [***] such shortfalls, damages and defects. [***]. 

		
	15.
	Supplied Materials.

		
	15.1
	The Parties may agree that COMPANY supplies certain or all raw materials or packaging, which are needed to manufacture the Product, to FRESENIUS (“Supplied Materials”). If the Parties agree on this, the Supplied Materials will be listed and specified in the relevant Annex of the applicable Quality Agreement and/or the applicable Product Schedule.

		
	15.2
	COMPANY will provide Supplied Materials (as specified in the applicable Product Schedule or as specified in the relevant Annex of the applicable Quality Agreement), unless otherwise mutually agreed in writing by the Parties, [***], to the FRESENIUS manufacturing site for the Product, in such quantities and quality of the Supplied Materials as are required to enable FRESENIUS to manufacture and deliver the quantities and quality of Products ordered. FRESENIUS agrees (a) to use the Supplied Materials exclusively for the manufacturing of the Products under this Agreement, (b) to account for all Supplied Materials, (c) not to provide Supplied Materials to any third party without the express prior written consent of COMPANY, and (d) [***], to destroy or return to COMPANY all unused quantities of Supplied Materials according to COMPANY’s written directions.

		
	15.3
	If any Supplied Materials negatively deviate from the quality agreed to in writing by the Parties in the applicable Quality Agreement for such Supplied Materials or if the deliveries of Supplied Materials suffer shortfalls, damages, delays or defects not caused by FRESENIUS actions or inactions, FRESENIUS shall immediately notify COMPANY, and COMPANY shall promptly supply FRESENIUS with conforming Supplied Materials. Should COMPANY not be able to timely meet the requirements for Supplied Materials through no fault of FRESENIUS and therefore the Manufacturing is stopped, delayed, frustrated or otherwise blocked, the Parties will discuss in good faith the impact and how to deal with this situation and possible losses. [***]. 

		
	15.4
	Replacement: In the event of any loss or damage of any Supplied Materials delivered hereunder and needed for Manufacture of a Batch of Product, COMPANY shall replace and provide FRESENIUS with Supplied Materials according to the terms set forth in Section 15.2, [***]. The Supplied Material reimbursement costs will be as set forth in the applicable Product Schedule.

13

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	16.
	Testing and Acceptance of Product.

		
	16.1
	Testing by FRESENIUS. The Product will be Manufactured in accordance with the Manufacturing Process approved by COMPANY, and with GMP. Each Batch of Product will be sampled and tested by FRESENIUS against the Specifications, and as set forth in the applicable Quality Agreement. 

		
	16.2
	Provision of Records. If, based upon such tests and documentation review for the Batch, a Batch of Product conforms to the Specifications and was Manufactured according to GMP and the Manufacturing Process, then a Certificate of Analysis and a Certificate of Conformity will be completed and approved by FRESENIUS and delivered to COMPANY, and such Certificate of Analysis and Certificate of Conformity will include any other requirements set forth in the applicable Quality Agreement. This Certificate of Conformity, a Certificate of Analysis, raw data from quality control testing and analysis as defined in the relevant Appendix of the Quality Agreement, and a complete and accurate copy of the Batch records and any other documentation specified in the applicable Quality Agreement (collectively, the “Batch Documentation”) for each Batch of Product will be promptly delivered to COMPANY as an electronic copy. [***]. 

		
	16.3
	Review of Batch Documentation; Acceptance. COMPANY will review the Batch Documentation for each Batch of Product after delivery of the Batch Documentation and may test samples of the Batch of Product against the Specifications [***]. COMPANY will notify FRESENIUS in writing of its acceptance or rejection of such Batch within [***] of date of receipt (as set forth in Section 16.2) of the electronic copy of the complete Batch Documentation relating to such Batch, subject to Section 16.6. During this review period, the Parties agree to respond promptly, to any reasonable inquiry or request for a correction or change by the other Party with respect to such Batch Documentation. COMPANY has no obligation to accept a Batch if such Batch does not comply with the Specifications and/or was not Manufactured in compliance with GMP and/or the Manufacturing Process specified in the MBR for the Batch; [***]. If such notice is not given by COMPANY in the time period specified above, the Product is deemed to be delivered in the right quantities, in compliance with the Specifications, and Manufactured in accordance with GMP and the agreed Manufacturing Process subject to Section 16.6. 

		
	16.4
	Disputes. In case of any disagreement as to whether Product conforms to the applicable Specifications or was Manufactured in compliance with GMP or the agreed Manufacturing Process, the quality assurance representatives of the parties will work in good faith, which shall include providing such documents and samples as may be reasonably requested by the other Party, to resolve any such disagreement and COMPANY and FRESENIUS will follow their respective SOPs to determine the conformity of the Product to the Specifications, and the Manufacturing Process and GMP. If the foregoing discussions do not resolve the disagreement in a reasonable time [***].

		
	16.5
	Product Non-Compliance and Remedies. If [***] a Batch of Product fails to conform to the Specifications subject to Section 16.7 or was not Manufactured in compliance with GMP and the Manufacturing Process [***], then FRESENIUS will, at COMPANY’s sole option, promptly:

14

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	(a)
	Replace, as soon as reasonably possible, [***], the Product of a failed Batch by Manufacturing a compliant Batch of Product (i.e., the replacement Batch conforms to the Specifications and was Manufactured in accordance with GMP and the agreed to Manufacturing Process. [***]; 

or
		
	(b)
	[***].

		
	16.6
	Latent Defects. Notwithstanding anything to the contrary in Section 16.3, the provisions of Section 16.5 and the dispute mechanism in Section 16.4, will apply to any Batch of Product that is a non-conforming Batch as a result of a Latent Defect (defined below) if COMPANY advises FRESENIUS in writing of such Latent Defect within [***] of discovery of such Latent Defect. “Latent Defect” means [***]. 

		
	16.7
	Product Non-Compliance. Notwithstanding Section 16.5, if a Batch of Product fails to conform to the Specifications as a result of COMPANY-provided Supplied Materials that were defective when delivered to FRESENIUS, [***]. 

		
	16.8
	Disposition of Non-Conforming Product. The ultimate disposition of non-conforming Product will be the responsibility of [***]. 

		
	17.
	Insurance. The Parties shall maintain throughout the term of this Agreement and for [***] after effective termination or expiry of the Agreement a commercial liability insurance covering product liability and other consumer injuries arising from the sale of the Products in an amount of at least [***] per occurrence and [***] in the aggregate. At the request of a Party, the other Party shall provide documentation sufficient to show proof of such coverage.

		
	18.
	Indemnification; Limitation of Liability.

		
	18.1
	COMPANY shall defend, indemnify and hold harmless FRESENIUS and its Affiliates, and its and their respective officers, statutory representatives, directors, and employees, and agents (the “FRESENIUS Indemnitees”) from and against any and all Losses incurred by the FRESENIUS Indemnitees for or in connection with any claims brought by third parties against the FRESENIUS Indemnitees to the extent arising or related to (i) infringement of any third party rights by FRESENIUS from its use of COMPANY Background Intellectual Property [***], in accordance with the terms of this Agreement as determined by a court of competent jurisdiction, (ii) failure of COMPANY to conform with the stipulations under this Agreement or the applicable Quality Agreement, (iii) [***], (iv) breach of this Agreement by COMPANY; or (v) negligence or wilful misconduct of COMPANY Indemnitees. 

		
	18.2
	FRESENIUS shall defend, indemnify and hold harmless COMPANY and its Affiliates, and its and their respective officers, directors, and employees and agents (the “COMPANY Indemnitees”) from and against any and all Losses incurred by the COMPANY Indemnitees for or in connection with any claims brought by third parties against the COMPANY Indemnitees to the extent arising or related to (i) infringement of any third party rights by COMPANY from its use of FRESENIUS Background Intellectual Property in accordance with the terms of this Agreement, (ii) failure of FRESENIUS to conform with the stipulations under this Agreement or the applicable Quality Agreement due to its negligence, (iii) breach 

15

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

of this Agreement by FRESENIUS; or (iv) negligence or wilful misconduct of FRESENIUS Indemnitees.
		
	18.3
	Each Party must notify the other Party within [***] of receipt of any claims made by a third party for which the other Party might be liable under this Section 18. Subject to Section 18.4, the indemnifying Party will have the sole right to defend, negotiate, and settle such third-party claims. The indemnified Party will be entitled to participate in the defense of such matter and to employ counsel at its expense to assist in such defense; provided, however, that the indemnifying Party will have final decision-making authority regarding all aspects of the defense of any claim. The Party seeking indemnification will provide the indemnifying Party with such information and assistance as the indemnifying Party may reasonably request, at the expense of the indemnifying Party. 

		
	18.4
	Settlement. Neither Party will be responsible nor bound by any settlement of any claim nor by any suit made without its prior written consent; provided, however, that the indemnified Party will not unreasonably withhold or delay such consent. 

		
	18.5
	Limitation of Liability. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, [***]. NOTHING IN THIS SECTION 18.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY.

		
	18.6
	Liability Cap. EXCEPT FOR DAMAGES THAT ARE A RESULT OF [***], OR EITHER PARTY’S INDEMNIFICATION OBLIGATIONS, OR OBLIGATIONS TO MAKE PAYMENT UNDER THIS AGREEMENT, AS FAR AS PERMITTED BY LAW, THE AGGREGATE OF FRESENIUS’ LIABILITY AND OBLIGATION TO COMPANY FOR THIS AGREEMENT SHALL BE LIMITED TO [***] (AS DEFINED IN THE APPLICABLE PRODUCT SCHEDULE) AND THE GREATER OF [***] BY COMPANY IN THE [***] PRIOR TO WHEN THE CLAIM AROSE PER [***]. 

		
	19.
	Product Recall; Adverse Events.

		
	19.1
	Recalls. As between COMPANY and FRESENIUS, COMPANY shall have sole discretion over whether and under what circumstances to require the recall of a Product. COMPANY will inform FRESENIUS promptly of any need or desire for recall of Product and FRESENIUS shall cooperate with and give all reasonable and timely assistance to COMPANY in connection therewith. [***]. 

		
	19.2
	Adverse Events. COMPANY will be solely responsible for adverse event reporting relating to Product (or any product containing or comprised of Product). In the event FRESENIUS receives or becomes aware of any adverse event information which may be related to Product (or any product containing or comprised of Product), FRESENIUS will immediately or as otherwise defined in the Quality Agreement provide COMPANY with all such information in English in the form and by the process required by COMPANY. 

16

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	20.
	Intellectual Property. 

		
	20.1
	Background Intellectual Property; Licenses. This Agreement does not affect the ownership of a Party’s Background Intellectual Property which remains the property of such Party (or its licensors). FRESENIUS does not acquire a license or any other right to COMPANY’s Background Intellectual Property except for the limited purpose of carrying out its duties and obligations under this Agreement and that such limited, non-exclusive, license will expire upon the completion of such duties and obligations or the termination or expiration of this Agreement, whichever is the first to occur. FRESENIUS hereby grants to COMPANY a non-exclusive, transferable (in conjunction with a permitted assignment under Section 26.7), sublicensable (to Affiliates of COMPANY), royalty-free, license to COMPANY and its Affiliates to use FRESENIUS Background Intellectual Property only to the extent necessary to distribute, offer for sale, sell, import, export, and otherwise dispose of Product, limited to the longer of the time this Agreement is in force or all Product supplied under this Agreement is used.

		
	20.2
	Improvements. 

		
	(a)
	“Improvements” means all discoveries, inventions, developments, modifications, innovations, updates, enhancements, improvements, writings or rights, and other Intellectual Property that are made, discovered, conceived, created, invented, developed, or reduced to practice in the performance of Services under this Agreement.

		
	(b)
	All Improvements that relate solely to [***] will be the sole and exclusive property of FRESENIUS (“FRESENIUS Improvements”). To the extent that FRESENIUS Improvements relay to the Product, FRESENIUS will grant COMPANY and COMPANY hereby accepts a worldwide, perpetual, irrevocable, transferable, sub-licensable royalty-free license to the extent necessary to freely operate regarding those FRESENIUS Improvements. All other Improvements will be the sole and exclusive property of COMPANY (“COMPANY Improvements”). FRESENIUS will have a limited license to use Company Improvements on [***].

		
	(c)
	FRESENIUS agrees (i) to promptly disclose all COMPANY Improvements; (ii) that all COMPANY Improvements will be the sole and exclusive property of COMPANY; and (iii) that FRESENIUS will assign and does assign all COMPANY Improvements to COMPANY (or its designee) without additional compensation to FRESENIUS. FRESENIUS will take such steps as COMPANY may reasonably request (at COMPANY’S expense) to vest in COMPANY (or its designee) ownership of the COMPANY Improvements. COMPANY will have the exclusive right and option, but not the obligation, to prepare, file, prosecute, maintain and defend at its sole expense, any patent applications or patents that claim and/or cover the COMPANY Improvements. 

		
	(d)
	COMPANY agrees (i) to promptly disclose all FRESENIUS Improvements; (ii) that all FRESENIUS Improvements will be the sole and exclusive property of FRESENIUS; and (c) that COMPANY will assign and does assign all FRESENIUS Improvements to FRESENIUS (or its designee) without additional compensation to COMPANY. COMPANY will take such steps as FRESENIUS may reasonably request (at FRESENIUS’ expense) to vest in FRESENIUS (or its designee) ownership of the FRESENIUS Improvements. FRESENIUS will have the exclusive right and option, but 

17

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

not the obligation, to prepare, file, prosecute, maintain and defend at its sole expense, any patent applications or patents that claim and/or cover the FRESENIUS Improvements
		
	21.
	Confidentiality.

		
	21.1
	The Receiving Party shall

		
	(a)
	keep in strict confidence and in safe custody all Confidential Information of the Disclosing Party,

		
	(b)
	use the Confidential Information only for the purpose of performing its obligations under this Agreement or the reasonable exercise of rights granted to it under this Agreement,

		
	(c)
	not copy or otherwise reproduce any of the Confidential Information except as is reasonably necessary for the purpose of performing its obligations or reasonably exercising rights granted to it under this Agreement, and

		
	(d)
	disclose the Confidential Information only to Entitled Persons.

		
	21.2
	“Entitled Persons” are only the statutory representatives, members of corporate bodies and employees, contractors, consultants and agents as well as the professional advisors of (a) the Receiving Party and (b) the Receiving Party's Affiliates, in each case with a need to know and bound by written obligations of confidentiality and non-use no less restrictive than the terms of this Agreement. The Receiving Party shall (i) limit access to the Confidential Information to a minimum number of persons as necessary for the purpose of performing this Agreement (or exercise of rights granted under it) and (ii) advise all such persons of the confidentiality obligations at the time the Confidential Information is disclosed to them and (iii) procure that they comply with the terms of this Agreement as if they were a receiving party to it. The Receiving Party shall be liable for any non-compliance of such persons with the terms of this Agreement as if the Receiving Party was itself so non-compliant. 

		
	21.3
	The Receiving Party's obligations under this Agreement shall not apply to Confidential Information which it can demonstrate, by admissible proof:

		
	(a)
	was known to the Receiving Party at the date of disclosure of the Confidential Information by the Disclosing Party,

		
	(b)
	is after the date of disclosure acquired by the Receiving Party in good faith from an independent third party who is not subject to any obligation of confidentiality in respect of such information,

		
	(c)
	was at the time of its disclosure in the public knowledge or has become public knowledge during the term of this Agreement other than through a breach of this Agreement by the Receiving Party, or

		
	(d)
	is independently developed by the Receiving Party without access to any of the Confidential Information.

18

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	21.4
	If Confidential Information of the other Party is required to be disclosed by applicable law, judicial action of court of competent jurisdiction, regulation, the rules or regulations of a recognized stock exchange or listing authority, government department or agency or other regulatory authority, the Receiving Party will prior to any disclosure, promptly notify the Disclosing Party, and cooperate with it in its lawful measures of protection with regard to the Confidential Information prior to the actual disclosure, and any disclosure by the Receiving Party will be only to the extent legally required to make such disclosure. 

		
	21.5
	Upon the Disclosing Party's written request (which for Confidential Information not needed by the Receiving Party to perform its obligations or exercise its rights) may be made at any time and at the Disclosing Party's sole and exclusive discretion, the Receiving Party shall, to the extent permissible under applicable law, promptly (i) return to the Disclosing Party any Confidential Information provided by or on behalf of the Disclosing Party to the Receiving Party in physical form, including, but not limited to, product samples, and otherwise (ii) destroy the Confidential Information. The Receiving Party shall not be obliged to delete automatically generated computer back-up or archival copies of the Confidential Information generated in the ordinary course of information system procedures, provided that except as expressly provided herein, the Receiving Party shall make no use of such copies and retain such copies under controlled locked files.

		
	21.6
	This Section 21 shall survive the effect of termination or expiry of this Agreement for [***] therefrom.

		
	22.
	Non-Exclusivity.

		
	22.1
	FRESENIUS undertakes to manufacture and supply the Product non-exclusively to COMPANY.

		
	23.
	Term and Termination.

		
	23.1
	This Agreement shall become effective as of the Effective Date and unless earlier terminated as permitted by this Agreement, shall remain in full force and effect for a period of [***] from the later of the Effective Date or the completion of all Services under all accepted Purchase Orders issued prior to the [***] of the Effective Date (“Initial Term”). The term of this Agreement shall automatically be extended for subsequent periods of [***] (“Extension Term”) unless terminated by a Party [***] prior to the end of the Initial Term or prior to the end of each Extension Term.

		
	23.2
	This Agreement, and any Product Schedule, may be terminated by a Party with written notice to the other Party under the following conditions: 

		
	(a)
	in the event of a material breach of this Agreement, or a Product Schedule, the non-breaching Party may terminate this Agreement, or the applicable Product Schedule if after [***] written notice from the non-breaching Party specifying the breach the other Party fails to cure such breach within the [***] period; 

		
	(b)
	if otherwise explicitly stated in this Agreement;

		
	(c)
	if the other Party files a petition in bankruptcy or of insolvency, or is adjudicated insolvent, or takes advantage of the insolvency law in any state or country, or makes an assignment 

19

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

for the benefit of creditors, or a receiver, trustee or other court officer is applied for or appointed for its property (which, in the case of any involuntary proceeding or assignments, are not dismissed within [***]); 
		
	(d)
	by FRESENIUS if COMPANY undergoes a Change Of Control to a FRESENIUS Competitor (defined below). For this purpose, COMPANY shall notify FRESENIUS without undue delay of such Change Of Control and the identity of the then controlling FRESENIUS Competitor. In the event that FRESENIUS elects to exercise its right of termination under this Section 23.2(d), it must notify COMPANY within [***] of receipt of notice from COMPANY and unless a shorter period is agreed to with COMPANY, FRESENIUS will continue to supply COMPANY according to the terms of this Agreement and all its Attachments for [***] following the COMPANY’s receipt of notice of termination from FRESENIUS. [***].

		
	23.3
	COMPANY will have the right, in its sole discretion, to terminate this Agreement or any Product Schedule upon written notice if (i) FRESENIUS fails to obtain or maintain any material governmental licenses or approvals required in connection with the Services and FRESENIUS fails to re-instate material governmental licenses or approvals within [***]; or (ii) the FDA or other Authority in the Territory does not approve Product (or any product containing or comprised of Product) for marketing or withdraws marketing approval upon [***] prior written notice to FRESENIUS. If COMPANY has agreed in a pending Product Schedule to any minimum purchase quantity of Product, COMPANY shall remain responsible to purchase, prior to the effective date of such termination, [***].

		
	23.4
	Effect of Termination. 

FRESENIUS will, upon receipt of a termination notice from COMPANY or any other termination of this Agreement by either Party as well as expiration of the Agreement term, promptly cease performance of the applicable Services and will take all reasonable steps to mitigate the out-of-pocket expenses incurred in connection therewith. In particular, FRESENIUS will use its best efforts to: immediately cancel, to the greatest extent possible, any third party obligations; promptly inform COMPANY of any irrevocable commitments made in connection with any pending Services prior to termination; promptly try to return to the vendor for a refund all unused, unopened materials in  FRESENIUS’ possession that are related to any pending Services; provided, that COMPANY will have the option, but not the obligation, to take possession of any such materials; promptly inform COMPANY of the cost of any remaining unused, unreturnable materials ordered pursuant to any pending Services, and either deliver such materials to COMPANY (or its designee) or properly dispose of them, as instructed by COMPANY at the expense of COMPANY; and perform only those services and activities mutually agreed upon by COMPANY and FRESENIUS as being necessary or advisable in connection with the close-out of any pending Services. 
In case of COMPANY’s termination other than for cause, or FRESENIUS’ termination of the Agreement or this Product Schedule for cause, COMPANY shall pay compensation concerning the Product as follows:
		
	(a)
	FRESENIUS’ Price, as specified in Part C.1 of the relevant Product Schedule, as valid at the time of termination for all work in progress on non-ordered Product, including work on intermediates at the date of termination which are within COMPANY’s binding 

20

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Forecasts (Section 5 of the Agreement) or minimum purchase quantity (Section 5.3 of this Agreement); and 
		
	(b)
	FRESENIUS’ direct costs for raw materials, intermediates and other materials in stock at the date of termination and purchased for the use in the manufacture of the Product. The compensation under this sub-paragraph (b) is given provided that: 

(i) the raw materials, intermediates and other materials are to be used for Product volumes which are within COMPANY’s Forecasts and for a period not exceeding [***]; 
(ii) the raw materials, intermediates and other materials cannot reasonably be used for other purposes by FRESENIUS; and
(ii) COMPANY is entitled to collect such raw materials, intermediates and other materials for its own use or sale, without additional charge.
		
	23.5
	Neither termination nor expiry of this Agreement shall release either Party from fulfilling any obligations which may have been incurred prior to any such termination or expiry. Sections 1, 2.5 (last two sentences), 2.7, 5.3, 6.2 (last sentence only), 7, 9, 10, 12, 13, 15.2 (last sentence) and 15.4, 16 through 21, 23.2(d), 23.4 through 23.7, 24 through 26 shall survive expiration or termination of this Agreement, as shall any other provision which due to its nature is intended to survive. 

		
	23.6
	Every termination of this Agreement requires a written notice by registered mail or other permitted method as set forth in this Agreement. 

		
	23.7
	This Section 23 applies for the term and termination of any individual Product Schedule as well, as long as the term or the termination is not regulated differently in the Product Schedule.

		
	24.
	Representations and Warranties. 

		
	24.1
	FRESENIUS Representations and Warranties. FRESENIUS represents and warrants to COMPANY that:

		
	(a)
	it has the full power and right to enter into this Agreement and that there are no outstanding agreements, assignments, licenses, encumbrances or rights of any kind held by other parties, private or public, that are inconsistent with the provisions of this Agreement;

		
	(b)
	the execution and delivery of this Agreement by FRESENIUS has been authorized by all requisite corporate or company action and this Agreement is and will remain a valid and binding obligation of FRESENIUS, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors;

		
	(c)
	the Services will be performed with requisite care, skill and diligence, by individuals who are appropriately trained and qualified; and in accordance with Applicable Laws and industry standards, and Services under a Product Schedule will be performed in accordance with all applicable provisions of this Agreement and the Quality Agreement, 

21

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

including the Specifications made known to FRESENIUS in writing prior to execution of such Product Schedule. 
		
	(d)
	to the best of FRESENIUS’ knowledge, the use of the FRESENIUS Background Intellectual Property of FRESENIUS in the conduct and the provision of the Services will not violate any patent, trade secret or other proprietary or intellectual property rights of any third party and it will promptly notify COMPANY in writing should it become aware of any claims asserting such violation; 

		
	(e)
	at the time of delivery to COMPANY, the Product Manufactured under this Agreement (i) will have been Manufactured in accordance with GMP and all other Applicable Laws, the Manufacturing Process, the applicable Quality Agreement, and Specifications; (ii) will not be adulterated or misbranded under the FDCA or other Applicable Laws; and (iii) will not have been produced in violation of any applicable provisions of the Austrian labor laws, as amended; and 

		
	(f)
	FRESENIUS, its Affiliates, approved subcontractors, and each of their respective officers and directors, as applicable, and any person used by FRESENIUS, its Affiliates or approved subcontractors to perform Services under this Agreement: (a) have not been debarred and are not subject to a pending debarment pursuant to section 306 of the United States Food, Drug and Cosmetic Act, 21 U.S.C. § 335a; (b) are not ineligible to participate in any federal and/or state healthcare programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. 1320a-7b(f)); (c) are not disqualified by any government or regulatory authorities from performing specific services, and are not subject to a pending disqualification proceeding; and (d) have not been convicted of a criminal offense related to the provision of healthcare items or services and are not subject to any such pending action.  FRESENIUS will notify COMPANY immediately if FRESENIUS, its Affiliates, or approved subcontractors, or any person used to perform Services under this Agreement, or any of their respective officers or directors, as applicable, is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of FRESENIUS’ knowledge, is threatened.

		
	(g)
	FRESENIUS has adhered to, and shall continue to adhere to, the provisions of the U.S. Foreign Corrupt Practices Act of 1977, as amended, codified at 15 U.S.C. §§ 78dd-1, et seq. ("FCPA"), and to any other applicable anti-corruption or anti-kickback legislation. Neither FRESENIUS nor any of its or its affiliates employees, directors, officers, subcontractors, consultants, agents, or representatives (collectively, “Representatives”) has engaged or in the future shall engage in any activity that is prohibited by the FCPA, including bribery, kickbacks, payoffs, or other corrupt business practices. FRESENIUS further represents, warrants and covenants that it and its Representatives have not offered, paid, or authorized, and will not offer, pay, or authorize, directly or indirectly, any payment of money or anything of value to a foreign official (as that term is defined by the FCPA) to improperly seek to influence any foreign official or Authority, or foreign government entity decision-making to gain a commercial or other advantage for COMPANY.

		
	24.2
	COMPANY Representations and Warranties. COMPANY represents and warrants to FRESENIUS that:

22

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	(a)
	it has the full power and right to enter into this Agreement and that there are no outstanding agreements, assignments, licenses, encumbrances or rights held by other parties, private or public, that are inconsistent with the provisions of this Agreement; 

		
	(b)
	the execution and delivery of this Agreement by COMPANY has been authorized by all requisite corporate action and this Agreement is and will remain a valid and binding obligation of COMPANY, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors;

		
	(c)
	to the best of COMPANY’s knowledge, the use of the COMPANY Background Intellectual Property in the conduct and the provision of the Services will not violate any patent, trade secret or other proprietary or intellectual property rights of any third party and it will promptly notify FRESENIUS in writing should it become aware of any claims asserting such violation

		
	(d)
	to the best of Company’s knowledge, Supplied Materials are, at the time of delivery, free from liens, defects, and in accordance with authorization from all relevant Authorities and with all specifications agreed to by the Parties for the Supplied Materials.

		
	24.3
	Disclaimer of Other Representations and Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

		
	25.
	Force Majeure.

		
	25.1
	Neither Party hereto shall be responsible or liable in any way for failure or delay in carrying out the terms of the Agreement resulting from any cause or circumstance beyond its reasonable control (a “Force Majeure”), including, but not limited to, fire, flood, other natural disasters, war, and civil commotion, provided that the Party so affected shall give prompt notice thereof to the other Party. 

		
	25.2
	No failure or delay set out in this Section shall terminate this Agreement, and each Party shall complete its obligations hereunder as promptly as reasonably practicable following cessation of the cause or circumstance of such failure or delay, provided, however, that if any of the above force majeure events continue to exist for more than [***] after the date of any notice given with regard thereto, either Party may terminate this Agreement with notice to the other.

		
	26.
	Miscellaneous.    

		
	26.1
	This Agreement constitutes the entire agreement between the Parties pertaining to the subject matter hereof and supersedes all prior agreements and understandings of the Parties with respect thereto. For avoidance of doubt, nothing in this Agreement changes the Development and Clinical Manufacturing Agreement dated [***], together with any amendments thereto. This Agreement may be amended, including this section, only by an amendment in writing that is signed by an authorized representative of each Party. All Exhibits referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. If there is any inconsistency between 

23

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

a Product Schedule or between any other Exhibit on the one hand and this Agreement on the other hand, the terms of this Agreement shall govern.
All Exhibits are listed as follows:
Exhibit 1: Product Schedule(s).
Exhibit 2: Form of Purchase Order 
		
	26.2
	The general terms and conditions of either of the Parties shall not be applicable even if they are contained in or referred to in any Purchase Order, order confirmation or other correspondence.

		
	26.3
	If any provision of this Agreement is determined, by a court with proper jurisdiction, to be invalid, illegal or unenforceable, the remaining provisions of this Agreement, to the extent permitted by law, shall remain in full force and effect. The Parties shall agree on a valid, legal or enforceable provision in lieu of the invalid, illegal or unenforceable provision that reflects the Parties’ intentions at the time of entering into this Agreement. The same shall apply if the Parties have, unintentionally, failed to address a certain matter in this Agreement.

		
	26.4
	No failure on the part of any Party to exercise or delay in exercising any right hereunder shall be deemed a waiver thereof except with respect to an express written waiver relating to a particular matter for a particular period of time signed by an authorized representative of the waiving Party, as applicable.

		
	26.5
	All notices hereunder shall be made in writing in the English language to the persons at the addresses set forth below, or such other person or address as may be designated by the respective Party to the other Party in the same manner. All notices must be given by (a) personal delivery, with receipt acknowledged; or (b) prepaid certified or registered mail, return receipt requested; or (c) prepaid recognized next business day or express delivery service. Notices will be effective upon receipt or at a later date stated in the notice. 

For FRESENIUS: 
[***]

For COMPANY:
AMAG Pharmaceuticals, Inc.
1100 Winter Street
Waltham, MA 02451
U.S.A.
Attn: Vice President of Technical Operations

With a copy to: 

AMAG Pharmaceuticals, Inc.
1100 Winter Street
Waltham, MA 02451
U.S.A.
Attn: General Counsel

24

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	26.6
	Nothing in this Agreement is intended to create an agency relationship, partnership or joint venture between the Parties. The relationship among the Parties is that of independent contractors. Neither COMPANY nor FRESENIUS shall present itself as affiliated with the other Party and nothing herein shall be construed as to grant either Party the right to refer to the other as a business partner or use the other’s trademarks and logos, unless specifically agreed upon in writing. This Agreement does not create an employer-employee relationship between COMPANY on the one hand and FRESENIUS or any employee, subcontractors, Affiliate of FRESENIUS, or any FRESENIUS personnel on the other. 

		
	26.7
	Neither this Agreement nor any rights or obligations hereunder may be assigned or transferred by either Party, in whole or in part, without the prior written consent of the other Party, except that a Party may assign this Agreement and its rights and obligations hereunder without the consent of the other Party to: (a) an Affiliate of such Party or (b) subject to the provisions in Section 23 regarding a Change of Control, any person or entity that acquires all or a substantial portion of the stock or assets, or line of business which the Product relates to, to such Party. Any purported assignment in violation of the preceding sentence will be void. Any permitted assignee will assume the rights and obligations of its assignor under this Agreement.

		
	26.8
	This Agreement shall be governed by and construed in accordance with the laws of Switzerland without regard to its principles of conflicts of law. The United Nations Convention on Contracts for the International Sale of Goods (CISG) and the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980 are excluded and shall not apply to this Agreement, including for clarity, Product Schedules, Purchase Order, or deliveries based hereon or thereon. 

		
	26.9
	Disputes.

		
	(a)
	The Parties will try to settle their differences amicably between themselves. Except for any disputes which are subject to Section 16.4, if any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement, including the performance or alleged non-performance of a Party of its obligations under this Agreement arises between the Parties (each a “Dispute”), a Party will, before initiating any proceedings pursuant to subsection b) of this Section, notify the other Party in writing of such Dispute. If the Parties are unable to resolve the Dispute within [***] of receipt of the written notice by the other Party, such dispute will be referred to an executive officer of COMPANY and an executive officer of FRESENIUS, or their designees, who will meet in person at least once and use their good faith efforts to resolve the Dispute within [***] after such referral.

		
	(b)
	[***]. 

		
	(c)
	[***].

		
	26.10
	Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

		
	26.11
	[***]. 

25

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

		
	26.12
	Headings. The headings used in this Agreement have been inserted for convenience of reference only and do not define or limit the provisions hereof. The Appendices to this Agreement are incorporated herein by reference and will be deemed a part of this Agreement.

		
	26.13
	Singular Terms. Except as otherwise expressly stated or unless the context otherwise requires, all references to the singular will include the plural and vice-versa.

		
	26.14
	Additional Interpretations. Unless otherwise expressly provided herein or the context of this Agreement otherwise requires, the words "include", "includes" and "including" will be deemed to be followed by the phrase "but not limited to", "without limitation", or words of similar import. 

		
	26.15
	Counterparts. This Agreement may be executed in one or more counterparts, all of which shall constitute one and the same agreement. The Agreement becomes valid only after the duly authorised representatives of both Parties have signed it.

[Signature Page Follows]

26

IN WITNESS WHEREOF, the authorized representatives of the Parties have duly executed this Agreement as of the Effective Date.
	
				
	SIGNED for and on behalf of
	 
	SIGNED for and on behalf of
	 

	Fresenius Kabi Austria GmbH
	 
	AMAG Pharmaceuticals, Inc.
	 

	 
	 
	 
	 

	/s/         Heinz Riesner
	 
	/s/ William K. Heiden
	 

	Signature
	 
	Signature
	 

	 
	 
	 
	 

	Name:    Heinz Riesner                
	 
	Name:     William K. Heiden            
	 

	 
	 
	 
	 

	Title:    General Manager            
	 
	Title:    CEO                    
	 

	
	
	SIGNED for and on behalf of

	Fresenius Kabi Austria GmbH

	 

	/s/     Tanja Greve

	Signature

	 

	Name:    Tanja Greve                

	Title:    Executive Vice President/CFO/GMP

	 

	 

	SIGNED for and on behalf of

	Fresenius Kabi Austria GmbH

	 

	/s/     Stefan     Czvitkovich

	Signature

	 

	Name:    Stefan Czvitkovich            

	Title:    Director PP Sterile PharmaceuticalsExhibit

EXHIBIT 4.1

PACIFICORP
(An Oregon Corporation)

TO

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.

(as successor to The Bank of New York Mellon)

As Trustee under PacifiCorp’s
Mortgage and Deed of Trust,
Dated as of January 9, 1989

_____________________

Thirtieth Supplemental Indenture
Dated as of March 1, 2019

Supplemental to PacifiCorp’s Mortgage and Deed of Trust
Dated as of January 9, 1989

_____________________

This Instrument Grants a Security Interest by a Transmitting Utility

This Instrument Contains After‐Acquired Property Provisions

THIRTIETH SUPPLEMENTAL INDENTURE

THIS INDENTURE, dated as of the 1st day of March, 2019, made and entered into by and between PACIFICORP, a corporation of the State of Oregon, whose address is 825 NE Multnomah Street, Portland, Oregon 97232 (hereinafter sometimes called the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (as successor to The Bank of New York Mellon), a national banking association whose address is 400 South Hope Street, Suite 400, Los Angeles, California 90071 (the “Trustee”), as Trustee under the Mortgage and Deed of Trust, dated as of January 9, 1989, as heretofore amended and supplemented (hereinafter called the “Mortgage”), is executed and delivered by the Company in accordance with the provisions of the Mortgage, this indenture (hereinafter called the “Thirtieth Supplemental Indenture”) being supplemental thereto. 
 
    WHEREAS, the Mortgage was or is to be recorded in the official records of the States of Arizona, California, Colorado, Idaho, Montana, New Mexico, Oregon, Utah, Washington and Wyoming and various counties within such states, which counties include or will include all counties in which this Thirtieth Supplemental Indenture is to be recorded; and 
WHEREAS, by the Mortgage the Company covenanted that it would execute and deliver such supplemental indenture or indentures and such further instruments and do such further acts as might be necessary or proper to carry out more effectually the purposes of the Mortgage and to make subject to the Lien of the Mortgage any property thereafter acquired, made or constructed and intended to be subject to the Lien thereof; and 
 
    WHEREAS, in addition to the property described in the Mortgage, the Company has acquired certain other property, rights and interests in property; and  

WHEREAS, the Company has executed, delivered, recorded and filed supplemental indentures as follows: 

2

	
				
	 
	 
	Dated as of
	 

	 
	 
	 
	 

	First 
	 
	March 31, 1989
	 

	Second 
	 
	December 29, 1989
	 

	Third 
	 
	March 31, 1991
	 

	Fourth 
	 
	December 31, 1991
	 

	Fifth 
	 
	March 15, 1992
	 

	Sixth 
	 
	July 31, 1992
	 

	Seventh 
	 
	March 15, 1993
	 

	Eighth 
	 
	November 1, 1993
	 

	Ninth 
	 
	June 1, 1994
	 

	Tenth 
	 
	August 1, 1994
	 

	Eleventh 
	 
	December 1, 1995
	 

	Twelfth 
	 
	September 1, 1996
	 

	Thirteenth 
	 
	November 1, 1998
	 

	Fourteenth 
	 
	November 15, 2001
	 

	Fifteenth 
	 
	June 1, 2003
	 

	Sixteenth 
	 
	September 1, 2003
	 

	Seventeenth 
	 
	August 1, 2004
	 

	Eighteenth
	 
	June 1, 2005
	 

	Nineteenth
	 
	August 1, 2006
	 

	Twentieth
	 
	March 1, 2007
	 

	Twenty-First
	 
	October 1, 2007
	 

	Twenty-Second
	 
	July 1, 2008
	 

	Twenty-Third
	 
	January 1, 2009
	 

	Twenty-Fourth
	 
	May 1, 2011
	 

	Twenty-Fifth
	 
	January 1, 2012
	 

	Twenty-Sixth
	 
	June 1, 2013
	 

	Twenty-Seventh
	 
	March 1, 2014
	 

	Twenty-Eighth
	 
	June 1, 2015
	 

	Twenty-Ninth
	 
	July 1, 2018
	 

and 
WHEREAS, the Company has heretofore issued, in accordance with the provisions of the Mortgage, bonds entitled and designated First Mortgage and Collateral Trust Bonds or First Mortgage Bonds, as the case may be, of the series and in the principal amounts as follows: 

3

	
												
	  
	  
	Series
	  
	Due
Date 
	  
	Aggregate Principal
Amount Issued 
	 
	 
	Aggregate Principal
Amount Outstanding 1

	First 
	 
	10.45% Series due January 9, 1990 
	 
	1/9/90
	 
	$ 
	500,000
	

	 
	$
	0

	Second 
	 
	Secured Medium-Term Notes, Series A 
	 
	various 
	 
	 
	250,000,000
	

	 
	 
	0

	Third 
	 
	Secured Medium-Term Notes, Series B 
	 
	various 
	 
	 
	200,000,000
	

	 
	 
	0

	Fourth 
	 
	Secured Medium-Term Notes, Series C 
	 
	various 
	 
	 
	300,000,000
	

	 
	 
	29,000,000

	Fifth 
	 
	Secured Medium-Term Notes, Series D 
	 
	various 
	 
	 
	250,000,000
	

	 
	 
	0

	Sixth 
	 
	C-U Series 
	 
	various 
	 
	 
	250,432,000
	

	 
	 
	0

	Seventh 
	 
	Secured Medium-Term Notes, Series E 
	 
	various 
	 
	 
	500,000,000
	

	 
	 
	155,000,000

	Eighth 
	 
	6 3/4% Series due April 1, 2005 
	 
	4/1/2005
	 
	 
	150,000,000
	

	 
	 
	0

	Ninth 
	 
	Secured Medium-Term Notes, Series F 
	 
	various 
	 
	 
	500,000,000
	

	 
	 
	140,000,000

	Tenth 
	 
	E-L Series 
	 
	various 
	 
	 
	71,200,000
	

	 
	 
	0

	Eleventh 
	 
	Secured Medium-Term Notes, Series G 
	 
	various 
	 
	 
	500,000,000
	

	 
	 
	100,000,000

	Twelfth 
	 
	Series 1994-1 Bonds 
	 
	various 
	 
	 
	216,470,000
	

	 
	 
	166,450,000

	Thirteenth 
	 
	Adjustable Rate Replacement Series 
	 
	2002
	 
	 
	13,234,000
	

	 
	 
	0

	Fourteenth 
	 
	9 3/8% Replacement Series due 1997 
	 
	1997
	 
	 
	50,000,000
	

	 
	 
	0

	Fifteenth 
	 
	Bond Credit Series Bonds 
	 
	various 
	 
	 
	498,589,753
	

	 
	 
	0

	Sixteenth 
	 
	Secured Medium-Term Notes, Series H 
	 
	various 
	 
	 
	500,000,000
	

	 
	 
	0

	Seventeenth  
	 
	5.65% Series due 2006 
	 
	11/1/06
	 
	 
	200,000,000
	

	 
	 
	0

	Eighteenth 
	 
	6.90% Series due November 15, 2011 
	 
	11/15/11
	 
	 
	500,000,000
	

	 
	 
	0

	Nineteenth 
	 
	7.70% Series due November 15, 2031 
	 
	11/15/31
	 
	 
	300,000,000
	

	 
	 
	300,000,000

	Twentieth 
	 
	Collateral Bonds, First 2003 Series 
	 
	12/1/14
	 
	 
	15,000,000
	

	 
	 
	0

	Twenty-First 
	 
	Collateral Bonds, Second 2003 Series
	 
	12/1/16
	 
	 
	8,500,000
	

	 
	 
	0

	Twenty-Second 
	 
	Collateral Bonds, Third 2003 Series 
	 
	1/1/14
	 
	 
	17,000,000
	

	 
	 
	0

	Twenty-Third 
	 
	Collateral Bonds, Fourth 2003 Series 
	 
	1/1/16
	 
	 
	45,000,000
	

	 
	 
	0

	Twenty-Fourth 
	 
	Collateral Bonds, Fifth 2003 Series 
	 
	11/1/25
	 
	 
	5,300,000
	

	 
	 
	5,300,000

	Twenty-Fifth 
	 
	Collateral Bonds, Sixth 2003 Series 
	 
	11/1/25
	 
	 
	22,000,000
	

	 
	 
	22,000,000

	Twenty-Sixth 
	 
	4.30% Series due 2008 
	 
	9/15/08
	 
	 
	200,000,000
	

	 
	 
	0

	Twenty-Seventh 
	 
	5.45% Series due 2013 
	 
	9/15/13
	 
	 
	200,000,000
	

	 
	 
	0

	Twenty-Eighth 
	 
	4.95% Series due 2014 
	 
	8/15/14
	 
	 
	200,000,000
	

	 
	 
	0

	Twenty-Ninth 
	 
	5.90% Series due 2034 
	 
	8/15/34
	 
	 
	200,000,000
	

	 
	 
	200,000,000

	Thirtieth
	 
	5.25% Series due 2035
	 
	6/15/35
	 
	 
	300,000,000
	

	 
	 
	300,000,000

	Thirty-First
	 
	6.10% Series due 2036
	 
	8/1/36
	 
	 
	350,000,000
	

	 
	 
	350,000,000

	Thirty-Second
	 
	5.75% Series due 2037
	 
	4/1/37
	 
	 
	600,000,000
	

	 
	 
	600,000,000

	Thirty-Third
	 
	6.25% Series due 2037
	 
	10/15/37
	 
	 
	600,000,000
	

	 
	 
	600,000,000

	Thirty-Fourth
	 
	5.65% Series due 2018
	 
	7/15/18
	 
	 
	500,000,000
	

	 
	 
	0

	Thirty-Fifth
	 
	6.35% Series due 2038
	 
	7/15/38
	 
	 
	300,000,000
	

	 
	 
	300,000,000

	Thirty-Sixth
	 
	5.50% Series due 2019
	 
	1/15/19
	 
	 
	350,000,000
	

	 
	 
	0

	Thirty-Seventh
	 
	6.00% Series due 2039
	 
	1/15/39
	 
	 
	650,000,000
	

	 
	 
	650,000,000

	Thirty-Eighth
	 
	3.85% Series due 2021
	 
	6/15/21
	 
	 
	400,000,000
	

	 
	 
	400,000,000

	Thirty-Ninth
	 
	2.95% Series due 2022
	 
	2/1/22
	 
	 
	450,000,000
	

	 
	 
	450,000,000

	Fortieth
	 
	4.10% Series due 2042
	 
	2/1/42
	 
	 
	300,000,000
	

	 
	 
	300,000,000

	Forty-First
	 
	2.95% Series due 2023
	 
	6/1/23
	 
	 
	300,000,000
	

	 
	 
	300,000,000

	Forty-Second
	 
	3.60% Series due 2024
	 
	4/1/24
	 
	 
	425,000,000
	

	 
	 
	425,000,000

	Forty-Third
	 
	3.35% Series due 2025
	 
	7/1/25
	 
	 
	250,000,000
	

	 
	 
	250,000,000

	Forty-Fourth
	 
	4.125% Series due 2049
	 
	1/15/49
	 
	 
	600,000,000
	

	 
	 
	600,000,000

4

______________________________

1 Amount outstanding as of March 1, 2019.

and
WHEREAS, Section 2.03 of the Mortgage provides that the form or forms, terms and conditions of and other matters not inconsistent with the provisions of the Mortgage, in connection with each series of bonds (other than the First Series) issued thereunder, shall be established in or pursuant to one or more Resolutions and/or shall be established in one or more indentures supplemental to the Mortgage, prior to the initial issuance of bonds of such series; and 
WHEREAS, Section 22.04 of the Mortgage provides, among other things, that any power, privilege or right expressly or impliedly reserved to or in any way conferred upon the Company by any provision of the Mortgage, whether such power, privilege or right is in any way restricted or is unrestricted, may be in whole or in part waived or surrendered or subjected to any restriction if at the time unrestricted or to additional restriction if already restricted, and the Company may enter into any further covenants, limitations, restrictions or provisions for the benefit of any one or more series of bonds issued thereunder and provide that a breach thereof shall be equivalent to a Default under the Mortgage, or the Company may cure any ambiguity contained therein, or in any supplemental indenture, or may (in lieu of establishment in or pursuant to a Resolution in accordance with Section 2.03 of the Mortgage) establish the forms, terms and provisions of any series of bonds other than said First Series, by an instrument in writing executed by the Company; and 
WHEREAS, the Company now desires to create two new series of bonds and (pursuant to the provisions of Section 22.04 of the Mortgage) to add to its covenants and agreements contained in the Mortgage certain other covenants and agreements to be observed by it; and

WHEREAS, the execution and delivery by the Company of this Thirtieth Supplemental Indenture, and the terms of the bonds of the Forty-Fifth Series and the Forty-Sixth Series herein referred to, have been duly authorized by the Board of Directors in or pursuant to appropriate Resolutions; 
Now, Therefore, This Indenture Witnesseth: 
That PACIFICORP, an Oregon corporation, in consideration of the premises and of good and valuable consideration to it duly paid by the Trustee at or before the ensealing and delivery of these presents, the receipt and sufficiency whereof is hereby acknowledged, and in order to secure the payment of both the principal of and interest and premium, if any, on the bonds from time to time issued under the Mortgage, according to their tenor and effect and the performance of all provisions of the Mortgage (including any instruments supplemental thereto and any modification made as in the Mortgage provided) and of such bonds, and to confirm the Lien of the Mortgage on certain after-acquired property, hereby mortgages, pledges and grants a security interest in (subject, however, to Excepted Encumbrances as defined in Section 1.06 of the Mortgage), unto The Bank of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon), as Trustee, and to its successor or successors in said trust, and to said Trustee and its successors and assigns forever, all properties of the Company real, personal and mixed, owned by the Company as of the date of the Mortgage and acquired by the Company after the date of the Mortgage, subject to the provisions of Section 18.03 of the Mortgage, of any kind or nature (except any herein or in the Mortgage expressly excepted), now owned or, subject to the provisions of Section 18.03 of the Mortgage, hereafter acquired by the Company (by purchase, consolidation, merger, donation, construction, erection or in any other way) and wheresoever situated (except such of such properties as are excluded by name or nature from the Lien hereof), including the properties described in Article V hereof, and further including (without limitation) all real estate, lands, easements, servitudes, licenses, permits, franchises, privileges, rights of way and other rights in or relating to real estate or the occupancy of the same; all power sites, flowage rights, water rights, water locations, water appropriations, ditches, flumes, reservoirs, reservoir sites, canals, raceways, waterways, dams, dam sites, aqueducts, and all other rights or means for appropriating, conveying, storing and supplying water; all rights of way and roads; all plants for the generation of electricity and other forms of energy (whether now known or hereafter developed) by steam, water, sunlight, chemical processes and/or (without limitation) all other sources of power (whether now known or hereafter developed); all power houses, gas plants, street lighting systems, standards and other equipment incidental thereto; all telephone, radio, television and other communications, image and data transmission systems, air-conditioning systems and equipment incidental thereto, water wheels, water works, water systems, steam and hot water plants, substations, lines, service and supply systems, bridges, culverts, tracks, ice or refrigeration plants and equipment, offices, buildings and other structures and the equipment thereof; all machinery, engines, boilers, dynamos, turbines, electric, gas and other machines, prime movers, regulators, meters, transformers, generators (including, but not limited to, engine-driven generators and turbogenerator units), motors, electrical, gas and mechanical appliances, conduits, cables, 

5

water, steam, gas or other pipes, gas mains and pipes, service pipes, fittings, valves and connections, pole and transmission lines, towers, overhead conductors and devices, underground conduits, underground conductors and devices, wires, cables, tools, implements, apparatus, storage battery equipment and all other fixtures and personalty; all municipal and other franchises, consents or permits; all lines for the transmission and distribution of electric current and other forms of energy, gas, steam, water or communications, images and data for any purpose including towers, poles, wires, cables, pipes, conduits, ducts and all apparatus for use in connection therewith and (except as herein or in the Mortgage expressly excepted) all the right, title and interest of the Company in and to all other property of any kind or nature appertaining to and/or used and/or occupied and/or enjoyed in connection with any property hereinbefore described; 
TOGETHER WITH all and singular the tenements, hereditaments, prescriptions, servitudes and appurtenances belonging or in anywise appertaining to the aforesaid property or any part thereof, with the reversion and reversions, remainder and remainders and (subject to the provisions of Section 13.01 of the Mortgage) the tolls, rents, revenues, issues, earnings, income, product and profits thereof, and all the estate, right, title and interest and claim whatsoever, at law as well as in equity, which the Company now has or may hereafter acquire in and to the aforesaid property and franchises and every part and parcel thereof;
IT IS HEREBY AGREED by the Company that, subject to the provisions of Section 18.03 of the Mortgage, all the property, rights and franchises acquired by the Company (by purchase, consolidation, merger, donation, construction, erection or in any other way) after the date hereof, except any herein or in the Mortgage expressly excepted, shall be and are as fully mortgaged and pledged hereby and as fully embraced within the Lien of the Mortgage as if such property, rights and franchises were now owned by the Company and were specifically described herein or in the Mortgage and mortgaged hereby or thereby; 
PROVIDED THAT the following are not and are not intended to be now or hereafter mortgaged or pledged hereunder, nor is a security interest therein hereby granted or intended to be granted, and the same are hereby expressly excepted from the Lien and operation of the Mortgage, namely: (1) cash, shares of stock, bonds, notes and other obligations and other securities not hereafter specifically pledged, paid, deposited, delivered or held under the Mortgage or covenanted so to be; (2) merchandise, equipment, apparatus, materials or supplies held for the purpose of sale or other disposition in the usual course of business or for the purpose of repairing or replacing (in whole or part) any rolling stock, buses, motor coaches, automobiles or other vehicles or aircraft or boats, ships or other vessels, and any fuel, oil and similar materials and supplies consumable in the operation of any of the properties of the Company; rolling stock, buses, motor coaches, automobiles and other vehicles and all aircraft; boats, ships and other vessels; all crops (both growing and harvested), timber (both growing and harvested), minerals (both in place and severed), and mineral rights and royalties; (3) bills, notes and other instruments and accounts receivable, judgments, demands, general intangibles and choses in action, and all contracts, leases and operating agreements not specifically pledged under the Mortgage or covenanted so to be; (4) the last day of the term of any lease or leasehold which may be or become subject to the Lien of the Mortgage; (5) electric energy, gas, water, steam, ice and other materials, forms of energy or products generated, manufactured, produced or purchased by the Company for sale, distribution or use in the ordinary course of its business; (6) any natural gas wells or natural gas leases or natural gas transportation lines or other works or property used primarily and principally in the production of natural gas or its transportation, primarily for the purpose of sale to natural gas customers or to a natural gas distribution or pipeline company, up to the point of connection with any distribution system; (7) the Company’s franchise to be a corporation; (8) any interest (as lessee, owner or otherwise) in the Wyodak Facility, including, without limitation, any equipment, parts, improvements, substitutions, replacements or other property relating thereto; and (9) any property heretofore released pursuant to any provision of the Mortgage and not heretofore disposed of by the Company; provided, however, that the property and rights expressly excepted from the Lien and operation of the Mortgage in the above subdivisions (2) and (3) shall (to the extent permitted by law) cease to be so excepted in the event and as of the date that the Trustee or a receiver for the Trustee shall enter upon and take possession of the Mortgaged and Pledged Property in the manner provided in Article XV of the Mortgage by reason of the occurrence of a Default; 

AND PROVIDED FURTHER, that as to any property of the Company that, pursuant to the after-acquired property provisions thereof, hereafter becomes subject to the lien of a mortgage, deed of trust or similar indenture that may in accordance with the Mortgage hereafter become designated as a Class “A” Mortgage, the Lien hereof shall at all times be junior and subordinate to the lien of such Class “A” Mortgage; 

TO HAVE AND TO HOLD all such properties, real, personal and mixed, mortgaged and pledged, or in which a security interest has been granted by the Company as aforesaid, or intended so to be (subject, however, to Excepted Encumbrances as defined in Section 1.06 of the Mortgage), unto The Bank of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon), as Trustee, and its successors and assigns forever; 

6

IN TRUST NEVERTHELESS, for the same purposes and upon the same terms, trusts and conditions and subject to and with the same provisos and covenants as are set forth in the Mortgage, this Thirtieth Supplemental Indenture being supplemental to the Mortgage; 
AND IT IS HEREBY COVENANTED by the Company that all the terms, conditions, provisos, covenants and provisions contained in the Mortgage shall affect and apply to the property hereinbefore described and conveyed, and to the estates, rights, obligations and duties of the Company and the Trustee and the beneficiaries of the trust with respect to said property, and to the Trustee and its successor or successors in the trust, in the same manner and with the same effect as if the said property had been owned by the Company at the time of the execution of the Mortgage, and had been specifically and at length described in and conveyed to said Trustee by the Mortgage as a part of the property therein stated to be conveyed. 
 
The Company further covenants and agrees to and with the Trustee and its successor or successors in such trust under the Mortgage, as follows: 

ARTICLE I

Forty-Fifth Series of Bonds

SECTION 1.01. There shall be a series of bonds designated “3.500% Series due 2029” (herein sometimes referred to as the Forty-Fifth Series), each of which shall also bear the descriptive title “First Mortgage Bond,” and the form thereof, which shall be established by or pursuant to a Resolution, shall contain suitable provisions with respect to the matters hereinafter in this Section specified. 
(I) Bonds of the Forty-Fifth Series shall mature on June 15, 2029 and shall be issued as fully registered bonds in the minimum denomination of two thousand dollars and, at the option of the Company, any multiple or multiples of one thousand dollars in excess thereof (the exercise of such option to be evidenced by the execution and delivery thereof). 
The Company reserves the right to establish, at any time, by or pursuant to a Resolution filed with the Trustee, a form of coupon bond, and or appurtenant coupons, for the Forty-Fifth Series and to provide for exchangeability of such coupon bonds with the bonds of the Forty-Fifth Series issued hereunder in fully registered form and to make all appropriate provisions for such purpose. 
Bonds of the Forty-Fifth Series need not be issued at the same time and such series may be reopened at any time, without notice to or the consent of any then-existing holder or holders of any bond of the Forty-Fifth Series, for issuances of additional bonds of the Forty-Fifth Series in an unlimited principal amount. Any such additional bonds will have the same interest rate, maturity and other terms as those initially issued, except for payment of interest accruing prior to the original issue date of such additional bonds and, if applicable, for the first interest payment date following such original issue date.
(II) Bonds of the Forty-Fifth Series shall bear interest at the rate of three and one-half per centum (3.500%) per annum payable semi-annually in arrears on June 15 and December 15 of each year (each, an “Interest Payment Date”). Bonds of the Forty-Fifth Series shall be dated and shall accrue interest as provided in Section 2.06 of the Mortgage. 
The initial Interest Payment Date is June 15, 2019. The amount of interest payable will be computed on the basis of a 360-day year consisting of twelve 30-day months. If any date on which interest is payable on any bond of the Forty-Fifth Series is not a Business Day, then payment of the interest payable on that date will be made on the next succeeding day which is a Business Day (and without any additional interest or other payment in respect of any delay), with the same force and effect as if made on such date.
    

7

Interest payable on any bond of the Forty-Fifth Series and punctually paid or duly provided for on any Interest Payment Date for such bond will be paid to the person in whose name the bond is registered at the close of business on the Record Date (as hereinafter specified) for such bond next preceding such Interest Payment Date; provided, however, that interest payable at maturity or upon earlier redemption will be payable to the person to whom principal shall be payable. So long as the bonds of the Forty-Fifth Series remain in book-entry only form, the “Record Date” for each Interest Payment Date shall be the close of business on the Business Day before the applicable Interest Payment Date. If the bonds of the Forty-Fifth Series are not in book-entry only form, the Record Date for each Interest Payment Date shall be the close of business on the 1st calendar day of the month in which the applicable Interest Payment Date occurs (whether or not a Business Day). 
“Business Day” means, for purposes of this Section (II), a day other than (i) a Saturday or a Sunday, or (ii) a day on which banking institutions in The City of New York are authorized or obligated by law or executive order to remain closed.
Any interest on any bond of the Forty-Fifth Series which is payable but is not punctually paid or duly provided for, on any Interest Payment Date for such bond (herein called “Defaulted Interest”), shall forthwith cease to be payable to the registered owner on the relevant Record Date for the payment of such interest solely by virtue of such owner having been such owner; and such Defaulted Interest may be paid by the Company, at its election in each case, as provided in subsection (i) or (ii) below: 

	
				
	  
	(i)
	The Company may elect to make payment of any Defaulted Interest on the bonds of the Forty-Fifth Series to the persons in whose names such bonds are registered at the close of business on a Special Record Date (as hereinafter defined) for the payment of such Defaulted Interest, which shall be fixed in the following manner: The Company shall, at least 30 days prior to the proposed date of payment, notify the Trustee in writing (signed by an Authorized Financial Officer of the Company) of the amount of Defaulted Interest proposed to be paid on each bond of the Forty-Fifth Series and the date of the proposed payment (which date shall be such as will enable the Trustee to comply with the next sentence hereof), and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the persons entitled to such Defaulted Interest as in this subsection provided and not to be deemed part of the Mortgaged and Pledged Property. Thereupon, the Trustee shall fix a record date (herein referred to as a “Special Record Date”) for the payment of such Defaulted Interest which date shall be not more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such Special Record Date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the Special Record Date therefor to be mailed, first-class postage prepaid, to each registered owner of a bond of the Forty-Fifth Series at his, her or its address as it appears in the bond register not less than 10 days prior to such Special Record Date. Notice of the proposed payment of such Defaulted Interest and the Special Record Date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the persons in whose names the bonds of the Forty-Fifth Series are registered at the close of business on such Special Record Date and shall no longer be payable pursuant to the following subsection (ii).

	  
	(ii)
	The Company may make payment of any Defaulted Interest on the bonds of the Forty-Fifth Series in any other lawful manner not inconsistent with the requirements of any securities exchange on which such bonds may be listed and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this subsection, such payment shall be deemed practicable by the Trustee.

 
Subject to the foregoing provisions of this Section, each bond of the Forty-Fifth Series delivered under the Mortgage upon transfer of or in exchange for or in lieu of any other bond shall carry all rights to interest accrued and unpaid, and to accrue, which were carried by such other bond and each such bond shall bear interest from such date, that neither gain nor loss in interest shall result from such transfer, exchange or substitution. 
(III) The principal of and interest and premium, if any, on each bond of the Forty-Fifth Series shall be payable at the office or agency of the Company in the Borough of Manhattan, The City of New York, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts or in such other currency or currency unit as shall be determined by or in accordance with the Resolution filed with the Trustee. 
    

8

(IV) Bonds of the Forty-Fifth Series shall not be redeemable prior to maturity at the option of any holder or holders of such bonds. Bonds of the Forty-Fifth Series shall be redeemable in whole at any time or in part from time to time prior to maturity at the option of the Company. Prior to March 15, 2029 (the “par call date”), the redemption price shall include accrued and unpaid interest to the redemption date on the bonds to be redeemed, plus the greater of (a) one hundred per centum (100%) of the principal amount of bonds then Outstanding to be redeemed, and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon that would be due if the bonds of the Forty-Fifth Series matured on the par call date (not including any portion of interest accrued as of the redemption date) discounted to but not including the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate, plus 15 basis points, as determined by an Independent Investment Banker. At any time on or after the par call date, the redemption price shall include accrued and unpaid interest to the redemption date on the bonds to be redeemed, plus one hundred percent (100%) of the principal amount of bonds then Outstanding to be redeemed. The Company shall give the Trustee notice of the redemption price referred to in the second preceding sentence immediately after the calculation thereof, and the Trustee shall have no responsibility for such calculation. If the Company elects to partially redeem the bonds of the Forty-Fifth Series, the bonds of the Forty-Fifth Series to be redeemed shall be selected by lot; provided, that if the bonds of the Forty-Fifth Series are in book-entry only form, interests in such bonds shall be selected for redemption by The Depository Trust Company in accordance with its standard procedures therefor.
“Business Day” means, for purposes of this Section (IV), a day other than (i) a Saturday or a Sunday, or (ii) a day on which banking institutions in The City of New York are authorized or obligated by law or executive order to remain closed.
“Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the bonds of the Forty-Fifth Series to be redeemed (that would be due if the bonds of the Forty-Fifth Series matured on the par call date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such bonds (the “Remaining Life”).
“Independent Investment Banker” means an investment banking institution of international standing appointed by the Company. 
“Reference Treasury Dealer” means a primary U.S. government securities dealer in New York City appointed by the Company. 
“Reference Treasury Dealer Quotation” means, with respect to the Reference Treasury Dealer and any redemption date, the average, as determined by the Company, of the bid and asked prices for the applicable Comparable Treasury Issue (expressed in each case as a percentage of its principal amount and quoted in writing to the Company by the Reference Treasury Dealer at 5:00 p.m. on the third business day in New York City preceding such redemption date).
“Treasury Rate” means, as of a given redemption date, the rate per annum equal to the semi-annual equivalent or interpolated (on a day-count basis) yield to maturity of the applicable Comparable Treasury Issue, assuming a price for such Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Reference Treasury Dealer Quotation for the applicable redemption date.
(V) Each bond of the Forty-Fifth Series may have such other terms as are not inconsistent with Section 2.03 of the Mortgage, and as may be determined by or in accordance with a Resolution filed with the Trustee. 
(VI) At the option of the registered owner, any bonds of the Forty-Fifth Series, upon surrender thereof for cancellation at the office or agency of the Company in the Borough of Manhattan, The City of New York, shall be exchangeable for a like aggregate principal amount of bonds of the same series and same terms of other authorized denominations. 
(VII) Bonds of the Forty-Fifth Series shall be transferable, subject to any restrictions thereon set forth in any such bond of the Forty-Fifth Series, upon the surrender thereof for cancellation, together with a written instrument of transfer, if required by the Company, duly executed by the registered owner or by his, her or its duly authorized attorney, at the office or agency of the Company in the Borough of Manhattan, The City of New York. Upon any transfer or exchange of bonds of the Forty-Fifth Series, the Company may make a charge therefor sufficient to reimburse it for any tax or taxes or other government charge, as provided in Section 2.08 of the Mortgage, but the Company hereby waives any right to make a charge in addition thereto for any exchange or transfer of bonds of the Forty-Fifth Series. 
    

9

(VIII) After the execution and delivery of this Thirtieth Supplemental Indenture and upon compliance with the applicable provisions of the Mortgage and this Thirtieth Supplemental Indenture, it is contemplated that there shall be issued bonds of the Forty-Fifth Series in an initial aggregate principal amount of Four Hundred Million Dollars (U.S. $400,000,000).

ARTICLE II

Forty-Sixth Series of Bonds

SECTION 2.01. There shall be a series of bonds designated “4.150% Series due 2050” (herein sometimes referred to as the Forty-Sixth Series), each of which shall also bear the descriptive title “First Mortgage Bond,” and the form thereof, which shall be established by or pursuant to a Resolution, shall contain suitable provisions with respect to the matters hereinafter in this Section specified. 
(I) Bonds of the Forty-Sixth Series shall mature on February 15, 2050 and shall be issued as fully registered bonds in the minimum denomination of two thousand dollars and, at the option of the Company, any multiple or multiples of one thousand dollars in excess thereof (the exercise of such option to be evidenced by the execution and delivery thereof). 
The Company reserves the right to establish, at any time, by or pursuant to a Resolution filed with the Trustee, a form of coupon bond, and or appurtenant coupons, for the Forty-Sixth Series and to provide for exchangeability of such coupon bonds with the bonds of the Forty-Sixth Series issued hereunder in fully registered form and to make all appropriate provisions for such purpose. 
Bonds of the Forty-Sixth Series need not be issued at the same time and such series may be reopened at any time, without notice to or the consent of any then-existing holder or holders of any bond of the Forty-Sixth Series, for issuances of additional bonds of the Forty-Sixth Series in an unlimited principal amount. Any such additional bonds will have the same interest rate, maturity and other terms as those initially issued, except for payment of interest accruing prior to the original issue date of such additional bonds and, if applicable, for the first interest payment date following such original issue date.
(II) Bonds of the Forty-Sixth Series shall bear interest at the rate of four and one hundred and fifty thousandths per centum (4.150%) per annum payable semi-annually in arrears on February 15 and August 15 of each year (each, an “Interest Payment Date”). Bonds of the Forty-Sixth Series shall be dated and shall accrue interest as provided in Section 2.06 of the Mortgage. 
The initial Interest Payment Date is August 15, 2019. The amount of interest payable will be computed on the basis of a 360-day year consisting of twelve 30-day months. If any date on which interest is payable on any bond of the Forty-Sixth Series is not a Business Day, then payment of the interest payable on that date will be made on the next succeeding day which is a Business Day (and without any additional interest or other payment in respect of any delay), with the same force and effect as if made on such date.
Interest payable on any bond of the Forty-Sixth Series and punctually paid or duly provided for on any Interest Payment Date for such bond will be paid to the person in whose name the bond is registered at the close of business on the Record Date (as hereinafter specified) for such bond next preceding such Interest Payment Date; provided, however, that interest payable at maturity or upon earlier redemption will be payable to the person to whom principal shall be payable. So long as the bonds of the Forty-Sixth Series remain in book-entry only form, the “Record Date” for each Interest Payment Date shall be the close of business on the Business Day before the applicable Interest Payment Date. If the bonds of the Forty-Sixth Series are not in book-entry only form, the Record Date for each Interest Payment Date shall be the close of business on the 1st calendar day of the month in which the applicable Interest Payment Date occurs (whether or not a Business Day). 
    

10

“Business Day” means, for purposes of this Section (II), a day other than (i) a Saturday or a Sunday, or (ii) a day on which banking institutions in The City of New York are authorized or obligated by law or executive order to remain closed. 
Any interest on any bond of the Forty-Sixth Series which is payable but is not punctually paid or duly provided for, on any Interest Payment Date for such bond (herein called “Defaulted Interest”), shall forthwith cease to be payable to the registered owner on the relevant Record Date for the payment of such interest solely by virtue of such owner having been such owner; and such Defaulted Interest may be paid by the Company, at its election in each case, as provided in subsection (i) or (ii) below: 

	
				
	  
	(i)
	The Company may elect to make payment of any Defaulted Interest on the bonds of the Forty-Sixth Series to the persons in whose names such bonds are registered at the close of business on a Special Record Date (as hereinafter defined) for the payment of such Defaulted Interest, which shall be fixed in the following manner: The Company shall, at least 30 days prior to the proposed date of payment, notify the Trustee in writing (signed by an Authorized Financial Officer of the Company) of the amount of Defaulted Interest proposed to be paid on each bond of the Forty-Sixth Series and the date of the proposed payment (which date shall be such as will enable the Trustee to comply with the next sentence hereof), and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the persons entitled to such Defaulted Interest as in this subsection provided and not to be deemed part of the Mortgaged and Pledged Property. Thereupon, the Trustee shall fix a record date (herein referred to as a “Special Record Date”) for the payment of such Defaulted Interest which date shall be not more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such Special Record Date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the Special Record Date therefor to be mailed, first-class postage prepaid, to each registered owner of a bond of the Forty-Sixth Series at his, her or its address as it appears in the bond register not less than 10 days prior to such Special Record Date. Notice of the proposed payment of such Defaulted Interest and the Special Record Date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the persons in whose names the bonds of the Forty-Sixth Series are registered at the close of business on such Special Record Date and shall no longer be payable pursuant to the following subsection (ii).

	  
	(ii)
	The Company may make payment of any Defaulted Interest on the bonds of the Forty-Sixth Series in any other lawful manner not inconsistent with the requirements of any securities exchange on which such bonds may be listed and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this subsection, such payment shall be deemed practicable by the Trustee.

 
Subject to the foregoing provisions of this Section, each bond of the Forty-Sixth Series delivered under the Mortgage upon transfer of or in exchange for or in lieu of any other bond shall carry all rights to interest accrued and unpaid, and to accrue, which were carried by such other bond and each such bond shall bear interest from such date, that neither gain nor loss in interest shall result from such transfer, exchange or substitution. 
(III) The principal of and interest and premium, if any, on each bond of the Forty-Sixth Series shall be payable at the office or agency of the Company in the Borough of Manhattan, The City of New York, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts or in such other currency or currency unit as shall be determined by or in accordance with the Resolution filed with the Trustee. 
    

11

(IV) Bonds of the Forty-Sixth Series shall not be redeemable prior to maturity at the option of any holder or holders of such bonds. Bonds of the Forty-Sixth Series shall be redeemable in whole at any time or in part from time to time prior to maturity at the option of the Company. Prior to August 15, 2049 (the “par call date”), the redemption price shall include accrued and unpaid interest to the redemption date on the bonds to be redeemed, plus the greater of (a) one hundred per centum (100%) of the principal amount of bonds then Outstanding to be redeemed, and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon that would be due if the bonds of the Forty-Sixth Series matured on the par call date (not including any portion of interest accrued as of the redemption date) discounted to but not including the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate, plus 20 basis points, as determined by an Independent Investment Banker. At any time on or after the par call date, the redemption price shall include accrued and unpaid interest to the redemption date on the bonds to be redeemed, plus one hundred percent (100%) of the principal amount of bonds then Outstanding to be redeemed. The Company shall give the Trustee notice of the redemption price referred to in the second preceding sentence immediately after the calculation thereof, and the Trustee shall have no responsibility for such calculation. If the Company elects to partially redeem the bonds of the Forty-Sixth Series, the bonds of the Forty-Sixth Series to be redeemed shall be selected by lot; provided, that if the bonds of the Forty-Sixth Series are in book-entry only form, interests in such bonds shall be selected for redemption by The Depository Trust Company in accordance with its standard procedures therefor.
“Business Day” means, for purposes of this Section (IV), a day other than (i) a Saturday or a Sunday, or (ii) a day on which banking institutions in The City of New York are authorized or obligated by law or executive order to remain closed.
“Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the bonds of the Forty-Sixth Series to be redeemed (that would be due if the bonds of the Forty-Sixth Series matured on the par call date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such bonds (the “Remaining Life”).
“Independent Investment Banker” means an investment banking institution of international standing appointed by the Company. 
“Reference Treasury Dealer” means a primary U.S. government securities dealer in New York City appointed by the Company. 
“Reference Treasury Dealer Quotation” means, with respect to the Reference Treasury Dealer and any redemption date, the average, as determined by the Company, of the bid and asked prices for the applicable Comparable Treasury Issue (expressed in each case as a percentage of its principal amount and quoted in writing to the Company by the Reference Treasury Dealer at 5:00 p.m. on the third business day in New York City preceding such redemption date).
“Treasury Rate” means, as of a given redemption date, the rate per annum equal to the semi-annual equivalent or interpolated (on a day-count basis) yield to maturity of the applicable Comparable Treasury Issue, assuming a price for such Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Reference Treasury Dealer Quotation for the applicable redemption date.
(V) Each bond of the Forty-Sixth Series may have such other terms as are not inconsistent with Section 2.03 of the Mortgage, and as may be determined by or in accordance with a Resolution filed with the Trustee. 
(VI) At the option of the registered owner, any bonds of the Forty-Sixth Series, upon surrender thereof for cancellation at the office or agency of the Company in the Borough of Manhattan, The City of New York, shall be exchangeable for a like aggregate principal amount of bonds of the same series and same terms of other authorized denominations. 
(VII) Bonds of the Forty-Sixth Series shall be transferable, subject to any restrictions thereon set forth in any such bond of the Forty-Sixth Series, upon the surrender thereof for cancellation, together with a written instrument of transfer, if required by the Company, duly executed by the registered owner or by his, her or its duly authorized attorney, at the office or agency of the Company in the Borough of Manhattan, The City of New York. Upon any transfer or exchange of bonds of the Forty-Sixth Series, the Company may make a charge therefor sufficient to reimburse it for any tax or taxes or other government charge, as provided in Section 2.08 of the Mortgage, but the Company hereby waives any right to make a charge in addition thereto for any exchange or transfer of bonds of the Forty-Sixth Series. 
    

12

(VIII) After the execution and delivery of this Thirtieth Supplemental Indenture and upon compliance with the applicable provisions of the Mortgage and this Thirtieth Supplemental Indenture, it is contemplated that there shall be issued bonds of the Forty-Sixth Series in an initial aggregate principal amount of Six Hundred Million Dollars (U.S. $600,000,000). 

ARTICLE III

The Company Reserves the Right to Amend Provisions

Regarding Properties Excepted from Lien of Mortgage

SECTION 3.01. The Company reserves the right, without any consent or other action by holders of bonds of the Ninth Series, or any other series of bonds subsequently created under the Mortgage (including the bonds of the Forty-Fifth Series and Forty-Sixth Series), to make such amendments to the Mortgage, as heretofore amended and supplemented, as shall be necessary in order to amend the first proviso to the granting clause of the Mortgage, which proviso sets forth the properties excepted from the Lien of the Mortgage, to add a new exception (10) which shall read as follows: 
“(10) allowances allocated to steam-electric generating plants owned by the Company or in which the Company has interests, pursuant to Title IV of the Clean Air Act Amendments of 1990, Pub. L. 101-549, Nov. 15, 1990, 104 Stat. 2399, 42 USC 7651, et seq., as now in effect or as hereafter supplemented or amended.” 
    
ARTICLE IV

Miscellaneous Provisions

SECTION 4.01. The right, if any, of the Company to assert the defense of usury against a holder or holders of bonds of the Forty-Fifth Series, the Forty-Sixth Series or any subsequent series shall be determined only under the laws of the State of New York.

SECTION 4.02. The terms defined in the Mortgage shall, for all purposes of this Thirtieth Supplemental Indenture, have the meanings specified in the Mortgage. The terms defined in Article I and in Article II of this Thirtieth Supplemental Indenture shall, for purposes of those respective Articles, have the meanings specified in Article I and Article II of this Thirtieth Supplemental Indenture, as the case may be.

SECTION 4.03. The Trustee hereby accepts the trusts hereby declared, provided, created or supplemented, and agrees to perform the same upon the terms and conditions herein and in the Mortgage, as hereby supplemented, set forth, including the following: 

The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Thirtieth Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made by the Company solely.  Each and every term and condition contained in Article XIX of the Mortgage shall apply to and form part of this Thirtieth Supplemental Indenture with the same force and effect as if the same were herein set forth in full, with such omissions, variations and insertions, if any, as may be appropriate to make the same conform to the provisions of this Thirtieth Supplemental Indenture. 

SECTION 4.04. Whenever in this Thirtieth Supplemental Indenture either of the Company or the Trustee is named or referred to, this shall, subject to the provisions of Articles XVIII and XIX of the Mortgage, be deemed to include the successors and assigns of such party, and all the covenants and agreements in this Thirtieth Supplemental Indenture contained by or on behalf of the Company, or by or on behalf of the Trustee, shall, subject as aforesaid, bind and inure to the respective benefits of the respective successors and assigns of such parties, whether so expressed or not. 

    

13

SECTION 4.05. Nothing in this Thirtieth Supplemental Indenture, expressed or implied, is intended, or shall be construed to confer upon, or to give to, any person, firm or corporation, other than the parties hereto and the holders of the bonds and coupons outstanding under the Mortgage, any right, remedy or claim under or by reason of this Thirtieth Supplemental Indenture or any covenant, condition, stipulation, promise or agreement hereof, and all the covenants, conditions, stipulations, promises and agreements in this Thirtieth Supplemental Indenture contained by or on behalf of the Company shall be for the sole and exclusive benefit of the parties hereto, and of the holders of the bonds and of the coupons outstanding under the Mortgage. 
SECTION 4.06. This Thirtieth Supplemental Indenture shall be executed in several counterparts, each of which shall be an original and all of which shall constitute but one and the same instrument. 

ARTICLE V

Specific Description of Property

The properties of the Company, owned as of the date hereof, and used (or held for future development and use) in connection with the Company’s electric utility systems, or for other purposes, and not previously described under the Mortgage, are as follows: 

Corral Substation
Internal Parcel No: ORCR-0021
County and State:  Crook County, Oregon
County Assessor number: 1515330000300

Legal Description:
Boundary line adjustment in Crook County, Oregon
Recorded October 2, 2018 and recorded in surveys #4302
Recorded October 2, 2018 Crook County Clerk as MF No. 289575

B.L.A. TRACT 1
A TRACT OF LAND BEING LOCATED IN THE SOUTHWEST ONE-QUARTER (SW1/4) OF SECTION 34, TOWNSHIP 15 SOUTH, RANGE 15 EAST OF THE WILLAMETTE MERIDIAN, MORE PARTICULARLY DESCRIBED AS FOLLOWS:  BEGINNING AT THE WEST ONE-QUARTER CORNER OF SAID SECTION 34 THENCE, SOUTH 09°11'06" EAST A DISTANCE OF 1727.72 FEET TO THE TRUE POINT OF BEGINNING OF THIS DESCRIPTION;  THENCE SOUTH 72°56'24" WEST A DISTANCE OF 270.14 FEET TO THE WEST LINE OF SAID SECTION 34;  THENCE NORTH 00°33'45" WEST ALONG THE WEST LINE OF SAID SECTION 34 A DISTANCE OF 954.58 FEET;  THENCE SOUTH 17°00'05" EAST A DISTANCE OF 915.28 FEET TO THE TRUE POINT OF BEGINNING, CONTAINING 2.84 ACRES, MORE OR LESS. 

14

B.L.A. TRACT 2
A PARCEL OF LAND BEING A PORTION OF PARCEL 2 OF PARTITION PLAT NO. 2010-01, RECORDS OF CROOK COUNTY, OREGON, LOCATED IN THE SOUTHEAST ONE-QUARTER (SE1/4) OF SECTION 33, TOWNSHIP 15 SOUTH, RANGE 15 EAST OF THE WILLAMETTE MERIDIAN, MORE PARTICULARLY DESCRIBED AS FOLLOWS:  BEGINNING AT THE EAST ONE-QUARTER CORNER OF SAID SECTION 33 THENCE, SOUTH 09°11'06" EAST A DISTANCE OF 1727.72 FEET;  THENCE SOUTH 72°56'24" WEST A DISTANCE OF 270.14 FEET TO THE EAST LINE OF SAID SECTION 33 AND THE TRUE POINT OF BEGINNING;  THENCE SOUTH 72°56'24" WEST A DISTANCE OF 960.13 FEET;  THENCE NORTH 17°00'05" WEST A DISTANCE OF 1350.00 FEET TO THE SOUTH LINE OF THE BONNEVILLE POWER ADMINISTRATION - PONDEROSA SUBSTATION CONVEYED IN DEED MF 66698, RECORDS OF CROOK COUNTY, OREGON;  THENCE NORTH 72°59'55" EAST ALONG SAID SOUTH LINE DISTANCE OF 490.27 FEET TO THE SOUTHWEST CORNER OF A TRACT OF LAND CONVEYED TO PACIFIC POWER & LIGHT IN DEEDS MF 72736, RECORDS OF CROOK COUNTY, OREGON;  THENCE NORTH 72°59'55" EAST ALONG THE SOUTH LINE OF SAID PACIFIC POWER & LIGHT TRACT A DISTANCE OF 408.40 FEET;  THENCE NORTH 42°59'55" EAST ALONG THE SOUTH LINE OF SAID PACIFIC POWER & LIGHT TRACT A DISTANCE OF 169.30 FEET;  THENCE ALONG THE SOUTH LINE OF SAID PACIFIC POWER & LIGHT TRACT AROUND A 370.00 FEET RADIUS CURVE TO THE LEFT, LONG CHORD BEARS NORTH 12°59'55" EAST A DISTANCE OF 370.00 FEET;  THENCE SOUTH 17°00'05" EAST A DISTANCE OF 838.54 FEET TO THE EAST LINE OF SAID SECTION 33;  THENCE SOUTH 00°33'45" EAST ALONG THE EAST LINE OF SAID SECTION 33 A DISTANCE OF 954.58 FEET TO THE TRUE POINT OF BEGINNING, CONTAINING 36.168 ACRES, MORE OR LESS

Mt Shasta Service Center
Internal Parcel No: CASI-0506
County and State:  Siskiyou County, California
County Assessor number: APN(s) 057-273-040 and 057-273-080 and 057-273-100

Legal Description:
Real property in the City of Mount Shasta, County of Siskiyou, State of California, described as follows: 
 
Lots 6,7,8,9,10,11,12,13 and 14 of Block "C", according to the Official Map of "C.C. Hunt's Addition to Sission, Siskiyou County, California, filed in the Office of the county Recorder in Book 1, town Maps, and numbered 31 therein, on February 28, 1910.  

15

Grants Pass Service Center
Internal Parcel No: ORJO-0506
County and State:  Josephine County, Oregon
County Assessor number: 36-05-19-DB-004000

Legal Description:
A tract of land situated in the Northwest Quarter of the Southeast Quarter of Section 19, Township 36 South, Range 5 West of the Willamette Meridian, Josephine County, Oregon, more particularly described as follows:

Commencing at the Southwest corner of the Northwest Quarter of the Southeast Quarter of said Section 19; thence North 1o 16' West a distance of 30.00 feet to a 3/4 inch diameter iron pipe on the North right of way line of Union Avenue; thence North 89o 57' East along said right of way line a distance of 703.80 (record 700.44) feet to a 5/8 inch diameter iron rod and being the Southeast corner of that property described in Volume 89 at Page 630 of Josephine County Deeds and the true point of beginning; thence North 89o 57' East (record South 88o 44' 30" East) along said right of way line a distance of 95.29 (record 98.088) feet to a 5/8 inch diameter iron rod; thence North 1o 09' 30" East (record North 1o 12' East) a distance of 167.76 (record 170.058) feet to a 1/2 inch diameter iron pipe; thence South 89o 29' East a distance of 199.27 feet to a 5/8 inch diameter iron rod; thence South a distance of 165.75 (record 170) feet to a 5/8 inch diameter iron rod located on the North right of way line of Union Avenue; thence North 89o 57' East (record East) along said right of way line a distance of 28.00 feet to a 5/8 inch diameter iron rod; thence North 11o 01' 30" West (record North 8o 08' 15" West) a distance of 14.59 (record 18.606) feet to a 3/4 inch diameter iron pipe located on the North bank of the Grants Pass Irrigation District Canal; thence North 61o 10' 30" East (record North 61o 11' 45" East) along said canal bank a distance of 180.06 feet to a one inch diameter iron pipe; thence North 9o 30' 27" West (record North 9o 28' 30" West) a distance of 228.24 (record 228.42) feet to a 3/4 inch diameter iron pipe; thence North 89o 02' 08" East (record North 89o 03' 30" East) a distance of 184.36 (record 184.51) feet to a 3/4 inch diameter iron pipe; thence North 02o 01' 53" West (record North 2o 04' 45" West) a distance of 42.32 (record 42.33) feet to a 3/4 inch diameter iron pipe; thence South 89o 27' 23" West (record South 89o 28' 45" West) a distance of 183.70 (record 183.84) feet to a 1/2 inch diameter iron pipe; thence North 0o 18' 45" West a distance of 107.77 (record 107.765) feet; thence South 89o 27' 45" West a distance of 36.995 feet; thence North a distance of 161.675 feet to the Southerly right of way line of the relocated Redwood Highway; thence South 84o 48' West along said right of way line a distance of 77.42 feet; thence South 85o 50' 30" West along said right of way line a distance of 149.94 feet; thence North 89o 27' 13" West (record North 89o 22' West) a distance of 159.41 (record 162.6) feet to the Easterly line of that property described in Volume 89 at Page 630 Josephine County Deed Records; thence South along said Easterly property line a distance of 621.15 (record 621.415) feet to the true point of beginning. EXCEPTING THEREFROM, all that portion conveyed to the State of Oregon, by and through its Department of Transportation, Highway Division by the Deed recorded March 4, 1977, Volume 322, Page 649, Records of Josephine County, Oregon.

16

Laramie service center
Parcel #: WYAL-5002
County and State: Albany, Wyoming
Tax ID: R0011208
Acreage: 1.38 acres 

Legal Description: 
Parcel I:
That portion of Block 52, Downey's Second Addition to the City of Laramie, Albany County, Wyoming, more particularly described as follows:
Beginning at the Southeast corner of Block 52; thence North 84° 01' West a distance of 438.83 feet along the South line of said Block 52 to the Southwest corner of said Block 52; thence North 06° 57' West a distance of 112.73 feet along the West line of said Block 52; thence North 86° 27' East a distance of 65.80 feet; thence a distance of 192.43 feet along a 01° 33' circular curve to the right (Delta is 02° 59', Tangent is 96.08', Radius is 3689.72'); thence North 00° 34' West a distance of 55.00 feet; thence a distance of 215.69 feet along a 01° 32' circular curve to the right (Delta is 03° 18', Tangent is 107.89', Radius is 3744.72') to a point being on the East line of said Block 52; thence South 05° 57' West a distance of 220.75 feet along the East line of said Block 52 to the point of beginning.  And including that portion of the vacated alley in said Block 52 situate within the boundaries of the above-described property. 
EXCEPTING therefrom, all that portion of said property lying West of a line parallel to West boundary of Second Street and 210 feet Westerly therefrom.
Parcel II:
A tract of land in the SW1/4 of Section 28, Township 16 North, Range 73 West of the 6th P.M., Albany County, Wyoming, more particularly described as follows:
The West one-half of vacated Second Street lying between the Easterly extensions of the North and South boundaries of said Block 52, Downey's Second Addition to the City of Laramie, and lying South of the Southerly right-of-way of Curtis Street.
Naples substation
Parcel #: UTUU-0014
County and State: Uintah, Utah
Tax ID: 06-053-0077
Acreage: 3.00 acres
Legal Description: 
A parcel of land situated in the Southwest Quarter of the Northeast Quarter of Section 8, Township 5 South, Range 22 East, Salt Lake Base and Meridian, described as follows:
Beginning at the Northwest Corner of the Grantor's land, said Northwest Corner being on the Northerly right-of-way line of U.S. Highway 40 at a point S 02°09'18" E 1333.23 feet along the section line and S 87°58'42" W 2225.49 feet along the 1/16 section line from the Northeast Corner of said Section 8; running thence N 87°58'42" E 670.68 feet along said Grantor's North boundary line; thence S 02°09'18" E 389.76 feet to the Southerly boundary line of the Grantor's land, said Southerly boundary line also being the Northerly right-of-way line of said U.S. Highway 40, thence N 61°53'34" W 776.49 feet along said Southerly boundary line to the point of beginning.

17

Containing 3.000 acres.
Access Road
A Right-of-Way 24 feet in width, being 24 feet perpendicularly distant Northerly of and adjoining the following described Southerly boundary line:
Beginning on the Southerly boundary line of the Grantor's land, also being the Northerly right-of-way line of U.S. Highway 40, at a point S 02°09'18" E 1333.23 feet along the section line, S 87°58'42" W 2225.49 feet along the 1/16 section line, and S 61°53'34" E 776.49 feet along said Southerly boundary line from the Northeast Corner of Section 8, Township 5 South, Range 22 East, Salt Lake Base and Meridian; running thence S 61°53'34" E 638.28 feet along the Southerly boundary line of said Grantor's land to the Southmost corner of Grantor's land, being on said land and being in the South Half of the Northeast Quarter of said Section 8.

Glendo substation
Parcel #: WYPL-0003
County: Platte
State: Wyoming
Tax ID: N/A
Acreage: 1.043 acres

Legal Description: 

Lot 4, Glendo Business Park, Platte County, Wyoming

18

IN WITNESS WHEREOF, PACIFICORP has caused its corporate name to be hereunto affixed, and this instrument to be signed and sealed by an Authorized Executive Officer of the Company, and its corporate seal to be attested to by its Assistant Secretary for and in its behalf, and The Bank of New York Mellon Trust Company, N.A. has caused its corporate name to be hereunto affixed, and this instrument to be signed and sealed by one of its Vice Presidents, and its corporate seal to be attested to by one of its Vice Presidents, all as of the day and year first above written.

 
	
					
	[SEAL] 
	 
	 
	PACIFICORP 

	

	 
	 
	By
	 /s/ Ryan Weems

	 
	 
	 
	 
	 

	 
	 
	 
	 
	Ryan Weems
Vice President, and Assistant Treasurer

	Attest:
	 /s/ Jeffery B. Erb
	 
	 
	 

	 
	 
	 
	 
	 

	 
	Jeffery B. Erb
Secretary 
	 
	 
	 

	

[SEAL] 
	 
	 
	 
	

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as trustee

	 
	 
	 
	By
	/s/ Karen Yu

	 
	 
	 
	 
	 

	 
	 
	 
	 
	Karen Yu
Vice President

	Attest:
	/s/ Mark A. Golder
	 
	 
	 

	 
	Mark A. Golder
Vice President
	 
	 
	 

	 
	 
	 
	 
	 

 
 

 

	
		
	STATE OF OREGON
	)

	  
	)

	COUNTY OF MULTNOMAH
	) SS.:

 
On this ____ day of _________, 2019, before me, _________________________________, a Notary Public in and for the State of Oregon, personally appeared Ryan Weems and Jeffery B. Erb, known to me to be Vice President and Assistant Treasurer and Secretary, respectively, of PACIFICORP, an Oregon corporation, who being duly sworn, stated that the seal affixed to the foregoing instrument is the corporate seal of said corporation and acknowledged this instrument to be the free, voluntary, and in all respects duly and properly authorized act and deed of said corporation. 

IN WITNESS WHEREOF, I have hereunto set my hand and official seal the day and year first above written.

 

	
					
	[SEAL] 
	 
	 
	 
	 

	 
	 
	 
	 
	

	 
	 
	 
	 
	Notary Public, State of Oregon 

 
 

ACKNOWLEDGMENT

	
	
	A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California 
County of _____________________________) 
On _________________________ before me, ___________________________________ 
(insert name and title of the officer) 
personally appeared ________________________________________________________, 
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. 
I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. 

WITNESS my hand and official seal.

Signature_____________________________     (Seal)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]